Enzyme

Abstract

The present invention relates to a variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with parent enzyme.

Description

REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of U.S. patent application Ser. No. 10/237,386 filed Sep. 9, 2002, which is a continuation-in-part of PCT/IB01/00426, filed Mar. 8, 2001, designating the U.S., published Sep. 13, 2001 as WO 01/66711 and claiming priority from GB 0005585.5 filed Mar. 8, 2000 and GB 0015751.1 filed Jun. 27, 2000. All of the above-mentioned applications, as well as all documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated by reference.

FIELD OF THE INVENTION

[0002] The present invention relates to mutant xylanase enzymes having an altered sensitivity to xylanase inhibitors. The present invention also relates to the use of these mutant enzymes in processing plant materials.

BACKGROUND TO THE INVENTION

[0003] For many years, endo-.beta.-1,4-xylanases (EC 3.2.1.8) (referred to herein as xylanases) have been used for the modification of complex carbohydrates derived from plant cell wall material. It is well known in the art that the functionality of different xylanases (derived from different micro organisms or plants) differs enormously.

[0004] Comprehensive studies characterising the functionality of xylanases have been done on well characterised and pure substrates (Kormelink et al., 1992). These studies show that different xylanases have different specific requirements with respect to substitution of the xylose backbone of the arabinoxylan (AX). Some xylanases require three un-substituted xylose residues to hydrolyse the xylose backbone; others require only one or two. The reasons for these differences in specificity is thought to be due to the three dimensional structure within the catalytic domains, which in turn is dependent on the primary structure of the xylanase, i.e. the amino acid sequence. However, the translation of these differences in the amino acid sequences into differences in the functionality of the xylanases, has up until now not been documented when the xylanase acts in a complex environment, such as plant material.

[0005] The xylanase substrates found in wheat (wheat flour), have traditionally been divided into two fractions: The water un-extractable AX (WU-AX) and the water extractable AX (WE-AX). The WU-AX:WE-AX ratio is approx. 70:30 in wheat flour. There have been numerous explanations as to why there are two different fractions of AX. The older literature (D'Appolonia and MacArthur (1976) and Montgomery and Smith (1955)) describes quite high differences in the substitution degree between WE-AX and WU-AX. The highest degree of substitution was found in WE-AX. This was used to explain why some of the AX was extractable. The high degree of substitution made the polymer soluble, compared to a lower substitution degree, which would cause hydrogen bonding between polymers and consequently precipitation.

[0006] The difference between the functionality of different xylanases has been thought to be due to differences in xylanase specificity and thereby their preference for the WU-AX or the WE-AX substrates.

[0007] In some applications (e.g. bakery) it is desirable to produce high molecular weight (HMW) soluble polymers from the WU-AX fraction. Such polymers have been correlated to a volume increase in bread making (Rouau, 1993; Rouau et al., 1994 and Courtin et al., 1999).

[0008] In other applications it is desirable to modify the HMW WU-AX, making the molecular weight lower, reducing their hydrocolloid effect and hence water-binding in the product (crackers, flour separation, etc.)

[0009] These different applications require different functionalities of the xylanases used to do the job. As mentioned above, the difference in functionality has been explained by the different substrate specificities of the xylanases.

SUMMARY OF THE INVENTION

[0010] By contrast to earlier studies, we have now shown that other factors are more important in determining xylanase functionality than the substrate specificity of the xylanases determined on pure well-characterised substrates. The data presented herein show that endogenous xylanase inhibitors dictate the functionality of the xylanases currently used in, for example, wheat flour systems. This means that a xylanase that normally modifies the WU-AX, giving increased dough liquid viscosity in a wheat flour system, has a different functionality if the endogenous xylanase inhibitor is absent in the wheat flour. Thus, our findings indicate that the design and application of uninhibited xylanases, for example, using site-directed mutagenesis could be a way to mimic the absence of xylanase inhibitors in various plant materials, giving new xylanases with completely new functionality. Such xylanases would be very effective in applications where a reduction in viscosity is required. The uninhibited xylanase would act rapidly on the AX, and be primarily influenced by its specific activity, rather than by endogenous inhibitors. From our studies, we consider that the inhibitory effects are likely to be far more important than the specific activity. Indeed our results show for the first time that there are 10 to 50 fold differences in inhibition levels between the family 11 xylanases.

[0011] Furthermore, we have gone on to design and test a series of xylanases modified by site-directed mutagenesis to demonstrate that xylanases can be produced that have reduced sensitivity to xylanase inhibitors present in plant materials. In particular, we have identified a number of residues in family 11 xylanases which influence the degree of inhibition of the xylanase.

[0012] Thus, it will be possible to produce variant xylanases having reduced sensitivity to xylanase inhibitors and hence altered functionality. This will, for example, allow a reduction in the amount of xylanase required in a number of applications such as animal feed, starch production, bakery, flour separation (wetmilling) and, paper and pulp production.

[0013] Accordingly, the present invention provides a variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent enzyme.

[0014] Here, the "parent enzyme" is the xylanase enzyme from which the variant xylanase enzyme is derived or derivable. With respect to the term "derivable", the variant need not necessarily be derived from the parent enzyme. Instead, the variant could be prepared, for example, by use of recombinant DNA techniques that utilise nucleotide sequence(s) encoding said variant xylanase sequence--i.e. here the nucleotide sequence(s) are similar to mutated nucleotide sequence(s) but they are not prepared by mutation of the parent nucleotide sequence(s). The variant may even be prepared by chemically modifying a parent enzyme.

[0015] For some embodiments the parent enzyme is the wild type enzyme. The term "wild type" is a term of art understood by skilled persons and includes a phenotype that is characteristic of most of the members of a species occurring naturally and contrasting with the phenotype of a mutant. Thus, in the present context, the wild type enzyme may be a form of the enzyme naturally found in most members of the relevant species. Generally, the relevant wild type enzyme in relation to the variant polypeptides of the invention is the most closely related corresponding wild type enzyme in terms of sequence homology. For example, for the particular mutant xylanases described in the examples, the corresponding wild type enzyme is the wild type B. subtilis xylanase A, more specifically the wild type B. subtilis xylanase A published by Paice et al., 1986 and shown as SEQ I.D. 1. However, where a particular wild type sequence has been used as the basis for producing a variant polypeptide of the invention, this will be the corresponding wild type sequence regardless of the existence of another wild type sequence that is more closely related in terms of amino acid sequence homology.

[0016] For some embodiments, preferably the variant polypeptide is derived from a family 11 xylanase.

[0017] One of our surprising findings is that in our studies so far a mutation in the xylanase active site has no measurable effect on inhibition against the xylanase inhibitor. This is in direct contrast to the mutation(s) that are made outside of the active site--which mutations are discussed in more detail below.

[0018] In a preferred aspect the amino acid modification is of one or more surface amino acid residues.

[0019] In a more preferred aspect the amino acid modification is of one or more solvent accessible residues. Here, the solvent is water.

[0020] In a more preferred aspect the amino acid modification is of one or more surface residues outside of the active site.

[0021] In a highly preferred aspect the amino acid modification is of one or more surface residues outside of the active site and which is/are at least 8% solvent accessible. Here, the solvent is water.

[0022] In a highly preferred aspect the amino acid modification is of one or more surface residues outside of the active site and which is/are at least 10% solvent accessible. Here, the solvent is water.

[0023] Solvent accessibility can be determined using Swiss-PdbViewer (version 3.5b1), which can be located via the internet at http:///www.expasy.ch/spdbv/mainpage.html. The Swiss-PdbViewer is presented by Glaxo Wellcome Experimental Research.

[0024] The surface amino acids of xylanase enzymes are determinable by a person skilled in the art.

[0025] By way of example, the B. subtilis amino acid sequence for xylanase A is shown as SEQ I.D. No. 1. With respect to this sequence, the surface amino acid residues are: [0026] Ala1-Trp6, Asn8, Thr10-Gly23, Asn25, Ser27, Asn29, Ser31-Asn32, Gly34, Thr43-Thr44, Ser46-Thr50, Asn52, Asn54, Gly56-Asn61, Asn63, Arg73-Leu76, Thr87-Arg89, Thr91-Lys95, Thr97, Lys99, Asp101-Gly102, Thr104, Thr109-Thr111, Tyr113-Asn114, Asp119-Thr124, Thr126, Gln133-Asn141, Thr143, Thr145, Thr147-Asn148, Asn151, Lys154-Gly157, Asn159-Leu160, Ser162-Trp164, Gln175, Ser177, Ser179, Asn181, Thr183, Trp185.

[0027] As indicated, the surface amino acids of other xylanase enzymes (such as Thermomyces lanuginosus xylanase A, whose coding nucleotide sequence is presented as SEQ ID No. 9) are determinable by a person skilled in the art.

[0028] Hence, for some aspects the present invention encompasses a variant xylanase polypeptide, or fragment thereof having xylanase activity, which variant xylanase polypeptide or fragment comprises one or more amino acid modifications at any one of amino acid residues: [0029] Ala1-Trp6, Asn8, Thr10-Gly23, Asn25, Ser27, Asn29, Ser31-Asn32, Gly34, Thr43-Thr44, Ser46-Thr50, Asn52, Asn54, Gly56-Asn61, Asn63, Arg73-Leu76, Thr87-Arg89, Thr91-Lys95, Thr97, Lys99, Asp101-Gly102, Thr104, Thr109-Thr111, Tyr113-Asn114, Asp119-Thr124, Thr126, Gln133-Asn141, Thr143, Thr145, Thr147-Asn148, Asn151, Lys154-Gly157, Asn159-Leu160, Ser162-Trp164, Gln175, Ser177, Ser179, Asn181, Thr183, Trp185 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or its/their equivalent positions in other homologous xylanase polypeptides.

[0030] Thus, in one embodiment, the present invention provides a variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications at any one of amino acid residues numbers: [0031] 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

[0032] In one embodiment, the present invention provides a variant xylanase polypeptide or fragment thereof having xylanase activity, comprising one or more amino acid modifications at any one of amino acid residues numbers 11, 12 and 13 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

[0033] Specific preferred examples of modifications made are presented in the Examples section herein.

[0034] For some embodiments, preferably the variant xylanase polypeptide, or fragment thereof having xylanase activity, comprises one or more amino acid modifications at any one of amino acid residues numbers: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 29, 30, 31, 32, 33, 34, 35, 36, 37, 61, 62, 63, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 173, 174, 175, 176, 177, 178 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

[0035] For convenience, we sometimes refer to the amino acid residues numbers: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 29, 30, 31, 32, 33, 34, 35, 36, 37, 61, 62, 63, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 173, 174, 175, 176, 177, 178 as BAND 1.

[0036] FIG. 1 shows the 3-D structure of B. subtilis xylanase having the amino acid sequence shown as SEQ I.D. No. 1. BAND 1 is depicted in FIG. 1 as the upper layer of the molecule and extends approximately 13 .ANG.ngstroms from the top of the molecule when the molecule is orientated as shown in FIG. 1. BAND 1 ends with the residue Phe 125 on the left hand side when viewing FIG. 1 and with the residue Asn 61 on the right hand side when viewing FIG. 1.

[0037] In addition, or in the alternative, for some embodiments, preferably the variant xylanase polypeptide, or fragment thereof having xylanase activity, comprises one or more amino acid modifications at any one of the other amino acid residues.

[0038] Preferably said other modifications may occur at any one or more of amino acid residues numbers: 3, 4, 5, 6, 7, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 108, 109, 110, 126, 127, 128, 129, 130, 131, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 179, 180, 181, 182, 183 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

[0039] For convenience, we sometimes refer to the amino acid residues numbers: 3, 4, 5, 6, 7, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 108, 109, 110, 126, 127, 128, 129, 130, 131, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 179, 180, 181, 182, 183 of the B. subtilis amino acid sequence shown as BAND 2.

[0040] Preferably said other modifications may occur at any one or more of the surface amino acid residues numbers: 3, 4, 5, 6, 19, 20, 21, 22, 23, 25, 27, 43, 44, 56, 57, 58, 59, 60, 73, 74, 75, 76, 87, 89, 91, 92, 93, 94, 109, 110, 126, 159, 160, 162, 163, 164, 179, 181, 183 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

[0041] Preferably, the present invention encompasses a variant xylanase polypeptide, or fragment thereof having xylanase activity, which comprises one or more amino acid modifications in BAND 1 and optionally/or BAND 2 of the B. subtilis amino acid sequence or their equivalent positions (bands) in other homologous xylanase polypeptides. Hence, the modification is in at least BAND 1; but could be in just BAND 2 alone.

[0042] The variant xylanase polypeptide may comprise other modifications in other amino acid residues, such as modification at any one of amino acid residues: 1, 2, 46, 47, 48, 49, 50, 51, 52, 53, 54, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 184, 185 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

[0043] The variant xylanase polypeptide may comprise other modifications in other surface amino acid residues, such as modification at any one of the surface amino acid residues: 1, 2, 46, 47, 48, 49, 50, 52, 54, 95, 97, 99, 101, 102, 104, 133, 134, 135, 136, 137, 138, 139, 140, 141, 143, 145, 147, 148, 151, 154, 155, 156, 157, 185 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

[0044] Preferably, the inhibitor is an inhibitor found naturally in plant tissues. Preferably the sensitivity of the variant xylanase enzyme to the inhibitor is reduced as compared to the parent xylanase enzyme.

[0045] The present invention also provides a nucleic acid molecule (a nucleotide sequence) encoding a polypeptide of the invention. Also provided is a vector comprising a nucleic acid of the invention, optionally operably linked to a regulatory sequence capable of directing expression of said nucleic acid in a suitable host cell. A host cell comprising a nucleic acid or a vector of the invention is also provided.

[0046] In another aspect the present invention provides a method of making a polypeptide of the invention comprising transforming a host cell with a nucleic acid encoding said polypeptide, culturing the transformed cell and expressing said polypeptide.

[0047] Our results show that these variant polypeptides have improved properties that make them suitable for a variety of applications, such as bakery, animal feed, starch production, flour separation (wetmilling) and, paper and pulp production.

[0048] Accordingly, the present invention also provides the use of a variant polypeptide of the invention in a method of modifying plant materials.

[0049] Also provided is the use of a variant polypeptide of the invention in baking. The invention further provides the use of a variant polypeptide of the invention in processing cereals, starch production and animal feed and the use of a variant polypeptide of the invention in processing wood, for example in enhancing the bleaching of wood pulp.

[0050] In a further aspect, the present invention provides a method of altering the sensitivity of a xylanase polypeptide to an inhibitor which method comprises modifying one or more amino acid residues of said enzyme selected from amino acid numbers 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 based on the amino acid numbering of B. subtilis xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides. Preferably the sensitivity is reduced.

[0051] Importantly, our results also show for the first time that xylanase inhibitors play an important role in determining the functionality of xylanase enzymes in a complex system, such as a plant material. By the term "functionality", we mean the biochemical properties of the xylanase in a given system. These properties include substrate specificity, K.sub.m and V.sub.max kinetic parameters (where appropriate) and the nature of the reaction products obtained by the action of the xylanase in that system. Functionality may also consequently be described in terms of the effect on the physical and/or chemical properties of the plant materials on which the xylanase acts, for example the extent to which the viscosity of the material is altered.

[0052] In the same way that variant xylanases may be used in a variety of processing applications, xylanase inhibitors may be used in a variety of processing applications such as bakery, wood pulp processing and cereal processing.

BRIEF DESCRIPTION OF THE DRAWINGS

[0053] The following Detailed Description, given by way of example, and not intended to limit the invention to specific embodiments described, may be understood in conjunction with the accompanying Figures, in which:

[0054] FIG. 1 shows the 3-D structure of B. subtilis xylanase having the amino acid sequence shown as SEQ I.D. No. 1; and,

[0055] FIG. 2 shows amino acid sequence alignment data in respect of 51 Family 11 xylanases.

DETAILED DESCRIPTION OF THE INVENTION

[0056] Although in general any molecular techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook et al., Molecular Cloning, A Laboratory Manual (1989) and Ausubel et al., Short Protocols in Molecular Biology (1999) 4.sup.th Ed, John Wiley & Sons, Inc.

A. Variant Xylanase Polypeptides

[0057] Xylanase enzymes have been reported from nearly 100 different organisms, including plants, fungi and bacteria. The xylanase enzymes are classified into several of the more than 40 families of glycosyl hydrolase enzymes. The glycosyl hydrolase enzymes, which include xylanases, mannanases, amylases, .beta.-glucanases, cellulases, and other carbohydrases, are classified based on such properties as the sequence of amino acids, the three dimensional structure and the geometry of the catalytic site (Gilkes, et al., 1991, Microbiol. Reviews 55: 303-315).

[0058] Of particular interest for baking applications are the enzymes classified in Family 11. All of these are xylanases and are known as the "Family 11 xylanases". Some publications refer to these synonymously as the Family G xylanases, but the term "Family 11 xylanases" will be used herein to refer to both Family G and Family 11 xylanases.

[0059] Table A lists a number of known Family 11 xylanases. Most of them have a molecular mass of about 21,000 Da. Three of the Family 11 xylanases (Clostridium stercorarium XynA, Streptomyces lividans XynB, and Thermomonospora fusca XynA) have a higher molecular mass of 31,000 to 50,000 Da. However, these xylanases have a catalytic core sequence of about 21,000 Da similar to the other Family 11 xylanases. The amino acid sequences of the Family 111 xylanases (or, for the larger enzymes, the catalytic core) show a high degree of similarity, usually with more than 40% identical amino acids in a proper amino acid alignment. The Family 11 xylanases, which are of bacterial, yeast, or fungal origin, share the same general molecular structure.

[0060] FIG. 2 shows amino acid sequence alignment data in respect of 51 Family 11 xylanases.

TABLE-US-00001 TABLE A Family 11 xylanases Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

Variant Xylanases of the Invention

[0061] A variant xylanase polypeptide of the invention is typically obtained by modifying a xylanase polypeptide by substituting, deleting or adding one or more amino acid residues within the amino acid sequence of the xylanase polypeptide. Preferably the modification comprises one or more amino acid substitutions. Modification of polypeptide sequences can be carried out using standard techniques such as site directed mutagenesis. The modification may also occur by chemical techniques--such as chemical modification of one or more amino acid residues.

[0062] The starting sequence may be a wild type sequence or a non-naturally occurring sequence, for example a derivative that has already been subjected to protein engineering. The xylanase sequence to be modified may be from any source, for example a bacterial, fungal or plant source. Preferably the xylanase sequence to be modified is that of a Family 11 xylanase, more preferably a Family 11 xylanase selected from Trichoderma reesei xylanase I, Trichoderma reesei xylanase II, Trichoderma harzianum xylanase, Trichoderma viride xylanase, Bacillus circulans xylanase A, Bacillus subtilis xylanase A, Aspergillus niger xylanase A, Aspergillus kawachii xylanase C, Aspergillus tubigensis xylanase A, Streptomyces lividans xylanase B, and Streptomyces lividans xylanase C.

[0063] In a particularly preferred embodiment, the xylanase sequence to be modified is the B. subtilis xylanase sequence shown as SEQ ID No. 1 or a homologue thereof. Preferably said homologue has at least 40, 50, 60 or 80% homology over at least 50 or 100 amino acid residues as determined using the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux et al., 1984, Nucleic Acids Research 12:387).

[0064] Specific modifications that are preferred according to the present invention include one or more amino acid substitutions at positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 based on the amino acid numbering of B. subtilis xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.

[0065] Particularly preferred substitutions include one or more of D11.PI.Y, D11.PI.N, D11.PI.F, D11.PI.K, D11.PI.S, D11.PI.W, G12.PI.F, G13.PI.F, I15.PI.K, N17.PI.K, N17.PI.Y, N17.PI.D, N29.PI.K, N29.PI.Y, N29.PI.D, S31.PI.K, S31.PI.Y, S31.PI.D, N32.PI.K, G34.PI.D, G34.PI.F, G34.PI.T, Y113.PI.A, Y113.PI.D, Y113.PI.K, N114.PI.A, N114.PI.D, N114.PI.F, N114.PI.K, D119.PI.K, D119.PI.Y, D119.PI.N, G120.PI.K, G120.PI.D, G120.PI.F, G120.PI.Y, G120.PI.N, D121.PI.N, D121.PI.K, D121.PI.F, D121.PI.A, R122.PI.D, R122.PI.F, R122.PI.A, T123.PI.K, T123.PI.Y, T123.PI.D, T124.PI.K, T124.PI.Y, T124.PI.D, Q175.PI.E, Q175.PI.S and Q175.PI.L (with reference to the amino acid sequence of B. subtilis xylanase) or their equivalents in other homologous xylanase polypeptides. Further references to specific residues of the B. subtilis xylanase shown as SEQ ID No. 1 will also include their equivalents in other homologous xylanase polypeptides.

[0066] A combination of mutations may be carried out, for example mutations at two or more of the above-mentioned residues. Examples of such combinations are presented in the Examples section herein.

[0067] In a further embodiment, the variant polypeptides of the invention may be purified and isolated naturally occurring mutant xylanases. Alternatively, mutant xylanases may be generated by subjecting organisms to mutagens and then screening for individuals comprising mutations in their xylanase genes. Naturally occurring mutants and mutants generated by random mutagenesis may be identified/screened using a variety of techniques such as PCR screening using suitable nucleic acid primers to amplify regions of xylanase genes and sequencing the resulting fragments.

[0068] Thus variant polypeptides of the invention include naturally occurring mutant xylanases (purified and isolated from the organisms in which they occur or obtained recombinantly), mutant xylanases obtained by random mutagenesis and mutant xylanases obtained by site-directed mutagenesis.

[0069] Variant polypeptides of the invention may also be subjected to further modifications that do not necessarily affect sensitivity to inhibitors, including any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the resultant amino acid sequence retains xylanase activity, preferably having at least substantially the same xylanase activity as the unmodified sequence.

[0070] Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

TABLE-US-00002 ALIPHATIC Non-polar G, A, P I, L, V Polar - uncharged C, S, T, M N, Q Polar - charged D, E K, R AROMATIC H, F, W, Y

[0071] Polypeptides of the invention also include fragments of the full length sequences mentioned above having xylanase activity.

[0072] Polypeptides of the invention may further comprise heterologous amino acid sequences, typically at the N-terminus or C-terminus, preferably the N-terminus. Heterologous sequence may include sequences that affect intra or extracellular protein targeting (such as leader sequences).

[0073] Polypeptides of the invention are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Polypeptides of the invention may also be produced as fusion proteins, for example to aid in extraction and purification. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences, such as a thrombin cleavage site. Preferably the fusion protein will not hinder the function of the protein sequence of interest.

[0074] The use of appropriate host cells is expected to provide for such post-translational modifications as may be needed to confer optimal biological activity on recombinant expression products of the invention.

[0075] Polypeptides of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is a polypeptide of the invention.

[0076] Variant polypeptides of the invention have altered sensitivity to xylanase inhibitors compared to the parent xylanase sequence--which may be a corresponding wild type xylanase. Preferably, variant polypeptides have reduced sensitivity to xylanase inhibitors. The term "altered sensitivity to xylanase inhibitors" means that extent to which the endo-.beta.-1,4-xylanase activity of a variant polypeptide of the invention is inhibited by the xylanase inhibitor is different to that of the parent xylanase enzyme--which may be the corresponding wild type xylanase. Preferably the extent to which the variant polypeptide is inhibited by the inhibitor is less than that of the parent xylanase enzyme--which may be the wild type protein. This may, for example, be due to a change in the three-dimensional structure of the variant polypeptide such that the inhibitor no longer binds with the same affinity as it does to the parent xylanase enzyme--which may be the wild type enzyme.

[0077] The sensitivity of the variant polypeptides of the invention to xylanase inhibitors can be assayed using, for example, the assay described in example 4 and below. A suitable inhibitor for use in the assay is the inhibitor purified from wheat flour in example 1. Other inhibitors are described below.

Xylanase Assay (Endo-.beta.-1,4-Xylanase Activity)

[0078] Xylanase samples are diluted in citric acid (0.1 M)--di-sodium-hydrogen phosphate (0.2 M) buffer, pH 5.0, to obtain approx. OD=0.7 in the final assay. Three dilutions of the sample and an internal standard with a defined activity are thermostated for 5 minutes at 40.degree. C. At time=5 minutes, 1 Xylazyme tab (crosslinked, dyed xylan substrate) is added to the enzyme solution. At time=15 minutes (or in some cases longer, depending on the xylanase activity present in the sample) the reaction is terminated, by adding 10 ml of 2% TRIS. The reaction mixture is centrifuged and the OD of the supernatant is measured at 590 nm. Taking into account the dilutions and the amount of xylanase, the activity (TXU, Total-Xylanase-Units) of the sample can be calculated relative to the standard.

Xylanase Inhibitors

[0079] As used herein, the term "xylanase inhibitor" refers to a compound, typically a protein, whose role is to control the depolymerisation of complex carbohydrates, such as arabinoxylan, found in plant cell walls. These xylanase inhibitors are capable of reducing the activity of naturally occurring xylanase enzymes as well as those of fungal or bacterial origin. Although the presence of xylanase inhibitors have been reported in cereal seeds (see for example McLauchlan et al 1999a; Rouau and Suget 1998) their impact on the efficacy of xylanase enzymes has not been extensively examined.

[0080] McLauchlan et al (1999a) disclose the isolation and characterisation of a protein from wheat that binds to and inhibits two family-11 xylanases. Likewise, WO 98/49278 demonstrates the effect of a wheat flour extract on the activity of a group of microbial xylanases all of which are classified as family 11 xylanases. Debyser et al. (1999) also disclose that endoxylanases from Aspergillus niger and Bacillus subtilis, which are both members of the family 11 xylanases were inhibited by a wheat xylanase inhibitor called TAXI. McLauchlan et al (1999b) teach that extracts from commercial flours such as wheat, barley, rye and maize are capable of inhibiting both family 10 and 11 xylanases.

[0081] The xylanase inhibitor may be any suitable xylanase inhibitor. By way of example, the xylanase inhibitor may be the inhibitor described in WO-A-98/49278 and/or the xylanase inhibitor described by Rouau, X. and Surget, A. (1998), McLauchlan, R., et al. (1999) and/or the xylanase inhibitor described in UK patent application number 9828599.2 (filed 23 Dec. 1998), UK patent application number 9907805.7 (filed 6 Apr. 1999) and UK patent application number 9908645.6 (filed 15 Apr. 1999).

Xylanase Inhibitor Assay

[0082] 100 .mu.l of an candidate inhibitor fraction, 250 .mu.l xylanase solution (containing 12 TXU microbial xylanase/ml) and 650 .mu.l buffer (0.1 M citric acid-0.2M di-sodium hydrogen phosphate buffer, pH 5.0) are mixed. The mixture is thermostated for 5 minutes at 40.0.degree. C. At time=5 minutes one Xylazyme tab is added. At time=15 minutes the reaction is terminated by adding 10 ml 2% TRIS. The reaction mixture is centrifuged (3500 g, 10 minutes, room temperature) and the supernatant is measured at 590 nm. The inhibition is calculated as residual activity compared to the blank. The blank is prepared the same way, except that the 100 .mu.l inhibitor is substituted with 100 .mu.l buffer (0.1 M citric acid-0.2 M di-sodium hydrogen phosphate buffer, pH 5.0).

Specific Xylanase Inhibitor

[0083] As indicated, a xylanase inhibitor that may be used in accordance with the present invention is the xylanase inhibitor described in UK patent application number 9828599.2 (filed 23 Dec. 1998), UK patent application number 9907805.7 (filed 6 Apr. 1999) and UK patent application number 9908645.6 (filed 15 Apr. 1999).

[0084] This endogenous endo-.beta.-1,4-xylanase inhibitor is obtainable from wheat flour. The inhibitor is a di-peptide, having a MW of about 40 kDa (as measured by SDS-PAGE or mass spectrometry) and a pI of about 8 to about 9.5.

[0085] Sequence analysis to date has revealed the that the inhibitor has at least one or more of the sequences presented as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7 and/or SEQ ID No. 8.

[0086] These inhibitors described in the prior art may also be used in assays to determine the sensitivity of a variant polypeptide of the invention to xylanase inhibitors. They may also be used as described below to modulate the functionality of a xylanase.

Polynucleotides

[0087] Polynucleotides of the invention comprise nucleic acid sequences encoding the variant polypeptide sequences of the invention. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides of the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed.

[0088] Polynucleotides of the invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of the invention.

Nucleotide Vectors and Host Cells

[0089] Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as E. coli, yeast and fungi.

[0090] Preferably, a polynucleotide of the invention in a vector is operably linked to a regulatory sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. The term "regulatory sequences" includes promoters and enhancers and other expression regulation signals.

[0091] Enhanced expression of the polynucleotide encoding the polypeptide of the invention may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions, which serve to increase expression and, if desired, secretion levels of the protein of interest from the chosen expression host and/or to provide for the inducible control of the expression of the polypeptide of the invention.

[0092] Aside from the promoter native to the gene encoding the polypeptide of the invention, other promoters may be used to direct expression of the polypeptide of the invention. The promoter may be selected for its efficiency in directing the expression of the polypeptide of the invention in the desired expression host.

[0093] In another embodiment, a constitutive promoter may be selected to direct the expression of the desired polypeptide of the invention. Examples of strong constitutive and/or inducible promoters which are preferred for use in fungal expression hosts are those which are obtainable from the fungal genes for xylanase (xlnA), phytase, ATP-synthetase, subunit 9 (oliC), triose phosphate isomerase (tpi), alcohol dehydrogenase (AdhA), .alpha.-amylase (amy), amyloglucosidase (AG--from the glaA gene), acetamidase (amdS) and glyceraldehyde-3-phosphate dehydrogenase (gpd) promoters.

[0094] Examples of strong yeast promoters are those obtainable from the genes for alcohol dehydrogenase, lactase, 3-phosphoglycerate kinase and triosephosphate isomerase.

[0095] Examples of strong bacterial promoters are the .alpha.-amylase and SP02 promoters as well as promoters from extracellular protease genes.

[0096] Hybrid promoters may also be used to improve inducible regulation of the expression construct.

[0097] Often, it is desirable for the polypeptide of the invention to be secreted from the expression host into the culture medium from where the polypeptide of the invention may be more easily recovered. According to the present invention, the polypeptide of the invention's native secretion leader sequence may be used to effect the secretion of the expressed polypeptide of the invention. However, an increase in the expression of the polypeptide of the invention sometimes results in the production of the protein in levels beyond that which the expression host is capable of processing and secreting, creating a bottleneck such that the protein product accumulates within the cell. Accordingly, the present invention also provides heterologous leader sequences to provide for the most efficient secretion of the polypeptide of the invention from the chosen expression host.

[0098] According to the present invention, the secretion leader may be selected on the basis of the desired expression host. A heterologous secretion leader may be chosen which is homologous to the other regulatory regions of the expression construct. For example, the leader of the highly secreted amyloglucosidase (AG) protein may be used in combination with the amyloglucosidase (AG) promoter itself, as well as in combination with other promoters. Hybrid signal sequences may also be used with the context of the present invention.

[0099] Examples of preferred heterologous secretion leader sequences are those originating from the fungal amyloglucosidase (AG) gene (glaA--both 18 and 24 amino acid versions e.g. from Aspergillus), the .alpha.-factor gene (yeasts e.g. Saccharomyces and Kluyveromyces) or the .alpha.-amylase gene (Bacillus).

[0100] Such vectors may be transformed into a suitable host cell as described above to provide for expression of a polypeptide of the invention. Thus, in a further aspect the invention provides a process for preparing polypeptides according to the invention which comprises cultivating a host cell transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and recovering the expressed polypeptides. Suitable host cells include, for example, fungal cells, such as Aspergillus and yeast cells, such as yeast cells of the genus Kluyveromyces or Saccharomyces. Other suitable host cells are discussed below.

[0101] The vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes. The most suitable selection systems for industrial micro-organisms are those formed by the group of selection markers which do not require a mutation in the host organism. Examples of fungal selection markers are the genes for acetamidase (amdS), ATP synthetase, subunit 9 (oliC), orotidine-5'-phosphate-decarboxylase (pvrA), phleomycin and benomyl resistance (benA). Examples of non-fungal selection markers are the bacterial G418 resistance gene (this may also be used in yeast, but not in fungi), the ampicillin resistance gene (E. coli), the neomycin resistance gene (Bacillus) and the E. coli uidA gene, coding for .beta.-glucuronidase (GUS). Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell.

[0102] A further embodiment of the invention provides host cells transformed or transfected with a polynucleotide of the invention. Preferably said polynucleotide is carried in a vector for the replication and expression of said polynucleotides. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells.

[0103] Bacteria from the genus Bacillus are very suitable as heterologous hosts because of their capability to secrete proteins into the culture medium. Other bacteria suitable as hosts are those from the genera Streptomyces and Pseudomonas.

[0104] Depending on the nature of the polynucleotide encoding the polypeptide of the invention, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a fungal host organism should be selected.

[0105] A heterologous host may also be chosen wherein the polypeptide of the invention is produced in a form which is substantially free from other xylanases. This may be achieved by choosing a host which does not normally produce such enzymes.

[0106] Examples of preferred expression hosts within the scope of the present invention are fungi such as Aspergillus species and Trichoderma species; bacteria such as Bacillus species, Streptomyces species and Pseudomonas species; and yeasts such as Kluyveromyces species and Saccharomyces species.

[0107] Particularly preferred expression hosts may be selected from Aspergillus niger, Aspergillus niger var. tubigenis, Aspergillus niger var. awamori, Aspergillus aculeatis, Aspergillus nidulans, Aspergillus oryzae, Trichoderma reesei, Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Kluyveromyces lactis and Saccharomyces cerevisiae.

[0108] According to the present invention, the production of the polypeptide of the invention can be effected by the culturing of microbial expression hosts, which have been transformed with one or more polynucleotides of the present invention, in a conventional nutrient fermentation medium.

[0109] The fermentation medium can comprise a known culture medium containing a carbon source (e.g. glucose, maltose, molasses, etc.), a nitrogen source (e.g. ammonium sulphate, ammonium nitrate, ammonium chloride, etc.), an organic nitrogen source (e.g. yeast extract, malt extract, peptone, etc.) and inorganic nutrient sources (e.g. phosphate, magnesium, potassium, zinc, iron, etc.). Optionally, an inducer may be added.

[0110] The selection of the appropriate medium may be based on the choice of expression hosts and/or based on the regulatory requirements of the expression construct. Such media are well-known to those skilled in the art. The medium may, if desired, contain additional components favouring the transformed expression hosts over other potentially contaminating microorganisms.

[0111] After fermentation, the cells can be removed from the fermentation broth by means of centrifugation or filtration. After removal of the cells, the variant polypeptide of the invention may then be recovered and, if desired, purified and isolated by conventional means.

Organisms

[0112] The term "organism" in relation to the present invention includes any organism that could comprise the nucleotide sequence coding for the variant xylanase protein according to the present invention and/or products obtained therefrom, wherein a transcriptional regulatory sequence can allow expression of the nucleotide sequence according to the present invention when present in the organism. Suitable organisms may include a prokaryote, fungus, yeast or a plant. For the xylanase aspect of the present invention, a preferable organism may be a bacterium, preferably of the genus Bacillus, more preferably Bacillus subtilis.

[0113] The term "transgenic organism" in relation to the present invention includes any organism that comprises the nucleotide sequence coding for the protein according to the present invention and/or products obtained therefrom, wherein the transcriptional regulatory sequence can allow expression of the nucleotide sequence according to the present invention within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

[0114] The term "transgenic organism" does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.

[0115] Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the nucleotide sequence coding for the amino acid sequence according to the present invention, constructs according to the present invention (including combinations thereof), vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention or the products thereof. The transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, the cell or organism.

Transformation of Host Cells/Host Organisms

[0116] As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include E. coli and Bacillus subtilis. Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press) and Ausubel et al., Short Protocols in Molecular Biology (1999), 4.sup.th Ed., John Wiley & Sons, Inc.

[0117] If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation--such as by removal of introns.

[0118] As mentioned above, a preferred host organism is of the genus Bacillus, such as Bacillus subtilis.

[0119] In another embodiment the transgenic organism can be a yeast. In this regard, yeasts have also been widely used as a vehicle for heterologous gene expression. The species Saccharomyces cerevisiae has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in Saccharomyces cerevisiae has been reviewed by Goodey et al (1987, Yeast Biotechnology, D R Berry et al, eds, pp 401-429, Allen and Unwin, London) and by King et al (1989, Molecular and Cell Biology of Yeasts, E F Walton and G T Yarronton, eds, pp 107-133, Blackie, Glasgow).

[0120] For several reasons Saccharomyces cerevisiae is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of Saccharomyces cerevisiae.

[0121] A review of the principles of heterologous gene expression in Saccharomyces cerevisiae and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

[0122] Several types of yeast vectors are available, including integrative vectors, which require recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors.

[0123] In order to prepare the transgenic Saccharomyces, expression constructs are prepared by inserting the nucleotide sequence of the present invention into a construct designed for expression in yeast. Several types of constructs used for heterologous expression have been developed. The constructs contain a promoter active in yeast fused to the nucleotide sequence of the present invention, usually a promoter of yeast origin, such as the GAL1 promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal peptide, is used. A terminator active in yeast ends the expression system.

[0124] For the transformation of yeast several transformation protocols have been developed. For example, a transgenic Saccharomyces according to the present invention can be prepared by following the teachings of Hinnen et al (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168).

[0125] The transformed yeast cells are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as LEU2, HIS4 and TRP1, and dominant antibiotic resistance markers such as aminoglycoside antibiotic markers, e.g. G418.

[0126] Another host organism is a plant. The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.

[0127] A transgenic plant of the invention may be produced from any plant such as the seed-bearing plants (angiosperms), and conifers. Angiosperms include dicotyledons and monocotyledons. Examples of dicotyledonous plants include tobacco, (Nicotiana plumbaginifolia and Nicotiana tabacum), arabidopsis (Arabidopsis thaliana), Brassica napus, Brassica nigra, Datura innoxia, Vicia narbonensis, Vicia faba, pea (Pisum sativum), cauliflower, carnation and lentil (Lens culinaris). Examples of monocotyledonous plants include cereals such as wheat, barley, oats and maize.

[0128] Techniques for producing transgenic plants are well known in the art. Typically, either whole plants, cells or protoplasts may be transformed with a suitable nucleic acid construct encoding a zinc finger molecule or target DNA (see above for examples of nucleic acid constructs). There are many methods for introducing transforming DNA constructs into cells, but not all are suitable for delivering DNA to plant cells. Suitable methods include Agrobacterium infection (see, among others, Turpen et al., 1993, J. Virol. Methods, 42: 227-239) or direct delivery of DNA such as, for example, by PEG-mediated transformation, by electroporation or by acceleration of DNA coated particles. Acceleration methods are generally preferred and include, for example, microprojectile bombardment. A typical protocol for producing transgenic plants (in particular monocotyledons), taken from U.S. Pat. No. 5,874,265, is described below.

[0129] An example of a method for delivering transforming DNA segments to plant cells is microprojectile bombardment. In this method, non-biological particles may be coated with nucleic acids and delivered into cells by a propelling force. Exemplary particles include those comprised of tungsten, gold, platinum, and the like.

[0130] A particular advantage of microprojectile bombardment, in addition to it being an effective means of reproducibly stably transforming both dicotyledons and monocotyledons, is that neither the isolation of protoplasts nor the susceptibility to Agrobacterium infection is required. An illustrative embodiment of a method for delivering DNA into plant cells by acceleration is a Biolistics Particle Delivery System, which can be used to propel particles coated with DNA through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with plant cells cultured in suspension. The screen disperses the tungsten-DNA particles so that they are not delivered to the recipient cells in large aggregates. It is believed that without a screen intervening between the projectile apparatus and the cells to be bombarded, the projectiles aggregate and may be too large for attaining a high frequency of transformation. This may be due to damage inflicted on the recipient cells by projectiles that are too large.

[0131] For the bombardment, cells in suspension are preferably concentrated on filters. Filters containing the cells to be bombarded are positioned at an appropriate distance below the macroprojectile stopping plate. If desired, one or more screens are also positioned between the gun and the cells to be bombarded. Through the use of techniques set forth herein one may obtain up to 1000 or more clusters of cells transiently expressing a marker gene ("foci") on the bombarded filter. The number of cells in a focus which express the exogenous gene product 48 hours post-bombardment often range from 1 to 10 and average 2 to 3.

[0132] After effecting delivery of exogenous DNA to recipient cells by any of the methods discussed above, a preferred step is to identify the transformed cells for further culturing and plant regeneration. This step may include assaying cultures directly for a screenable trait or by exposing the bombarded cultures to a selective agent or agents.

[0133] An example of a screenable marker trait is the red pigment produced under the control of the R-locus in maize. This pigment may be detected by culturing cells on a solid support containing nutrient media capable of supporting growth at this stage, incubating the cells at, e.g., 18.degree. C. and greater than 180 .mu.Em.sup.-2s.sup.-1, and selecting cells from colonies (visible aggregates of cells) that are pigmented. These cells may be cultured further, either in suspension or on solid media.

[0134] An exemplary embodiment of methods for identifying transformed cells involves exposing the bombarded cultures to a selective agent, such as a metabolic inhibitor, an antibiotic, herbicide or the like. Cells which have been transformed and have stably integrated a marker gene conferring resistance to the selective agent used, will grow and divide in culture. Sensitive cells will not be amenable to further culturing.

[0135] To use the bar-bialaphos selective system, bombarded cells on filters are resuspended in nonselective liquid medium, cultured (e.g. for one to two weeks) and transferred to filters overlaying solid medium containing from 1-3 mg/l bialaphos. While ranges of 1-3 mg/l will typically be preferred, it is proposed that ranges of 0.1-50 mg/l will find utility in the practice of the invention. The type of filter for use in bombardment is not believed to be particularly crucial, and can comprise any solid, porous, inert support.

[0136] Cells that survive the exposure to the selective agent may be cultured in media that supports regeneration of plants. Tissue is maintained on a basic media with hormones for about 2-4 weeks, then transferred to media with no hormones. After 2-4 weeks, shoot development will signal the time to transfer to another media.

[0137] Regeneration typically requires a progression of media whose composition has been modified to provide the appropriate nutrients and hormonal signals during sequential developmental stages from the transformed callus to the more mature plant. Developing plantlets are transferred to soil, and hardened, e.g., in an environmentally controlled chamber at about 85% relative humidity, 600 ppm CO.sub.2, and 250 .mu.Em.sup.-2s.sup.-1 of light. Plants are preferably matured either in a growth chamber or greenhouse. Regeneration will typically take about 3-12 weeks. During regeneration, cells are grown on solid media in tissue culture vessels. An illustrative embodiment of such a vessel is a petri dish. Regenerating plants are preferably grown at about 19.degree. C. to 28.degree. C. After the regenerating plants have reached the stage of shoot and root development, they may be transferred to a greenhouse for further growth and testing.

[0138] Genomic DNA may be isolated from callus cell lines and plants to determine the presence of the exogenous gene through the use of techniques well known to those skilled in the art such as PCR and/or Southern blotting.

[0139] Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).

[0140] Thus, in one aspect, the present invention relates to a vector system which carries a construct encoding a variant xylanase polypeptide according to the present invention and which is capable of introducing the construct into the genome of a plant.

[0141] The vector system may comprise one vector, but it can comprise at least two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.

[0142] One extensively employed system for transformation of plant cells with a given promoter or nucleotide sequence or construct is based on the use of a Ti plasmid from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes (An et al. (1986), Plant Physiol. 81, 301-305 and Butcher D. N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D. S. Ingrams and J. P. Helgeson, 203-208).

[0143] Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above.

B. Uses

[0144] In a general sense, a variant xylanase of the invention may be used to alter, for example reduce, the viscosity derived from the presence of hemicellulose or arabinoxylan in a solution or system comprising plant cell wall material. Typically said plant cell wall materials will comprise one or more xylanase inhibitors.

[0145] Specifically, a variant xylanase of the invention may be used in processing plant materials for use as foodstuffs, such as animal feed, in starch production, in baking and in the processing of wood pulp to make paper.

Preparation of Foodstuffs

[0146] A variant xylanase of the invention may be used to process plant materials such as cereals that are used in foodstuffs including animal feed. As used herein, the term "cereal" means any kind of grain used for food and/or any grass producing this grain such as but not limited to any one of wheat, milled wheat, barley, maize, sorghum, rye, oats, triticale and rice or combinations thereof. In one preferred embodiment, the cereal is a wheat cereal.

[0147] The xylan in the food and/or feed supplement is modified by contacting the xylan with the variant xylanase of the present invention.

[0148] As used herein, the term "contacting" includes but is not limited to spraying, coating, impregnating or layering the food and/or feed supplement with the variant xylanase enzyme of the present invention.

[0149] In one embodiment, the food and/or feed supplement of the present invention may be prepared by mixing the variant xylanase enzyme directly with a food and/or feed supplement. By way of example, the variant xylanase enzyme may be contacted (for example, by spraying) onto a cereal-based food and/or feed supplement such as milled wheat, maize or soya flour.

[0150] It is also possible to incorporating the variant xylanase enzyme it into a second (and different) food and/or feed or drinking water which is then added to the food and/or feed supplement of the present invention. Accordingly, it is not essential that the variant xylanase enzyme provided by the present invention is incorporated into the cereal-based food and/or feed supplement itself, although such incorporation forms a particularly preferred aspect of the present invention.

[0151] In one embodiment of the present invention, the food and/or feed supplement may be combined with other food and/or feed components to produce a cereal-based food and/or feed. Such other food and/or feed components may include one or more other (preferably thermostable) enzyme supplements, vitamin food and/or feed supplements, mineral food and/or feed supplements and amino acid food and/or feed supplements. The resulting (combined) food and/or feed supplement comprising possibly several different types of compounds can then be mixed in an appropriate amount with the other food and/or feed components such as cereal and protein supplements to form a human food and/or an animal feed.

[0152] In one preferred embodiment, the food and/or feed supplement of the present invention can be prepared by mixing different enzymes having the appropriate activities to produce an enzyme mix. By way of example, a cereal-based food and/or feed supplement formed from e.g. milled wheat or maize may be contacted (e.g. by spraying) either simultaneously or sequentially with the xylanase enzyme and other enzymes having appropriate activities. These enzymes may include but are not limited to any one or more of an amylase, a glucoamylase, a mannanase, an a galactosidase, a phytase, a lipase, a glucanase, an-arabinofuranosidase, a pectinase, a protease, a glucose oxidase, a hexose oxidase and a xylanase. Enzymes having the desired activities may for instance be mixed with the xylanase of the present invention either before contacting these enzymes with a cereal-based food and/or feed supplement or alternatively such enzymes may be contacted simultaneously or sequentially on such a cereal based supplement. The food and/or feed supplement is then in turn mixed with a cereal-based food and/or feed to prepare the final food and/or feed. It is also possible to formulate the food and/or feed supplement as a solution of the individual enzyme activities and then mix this solution with a food and/or feed material prior to processing the food and/or feed supplement into pellets or as a mash.

Bakery Products

[0153] The present invention provides the use of a variant xylanase polypeptide of the invention in a process for preparing a foodstuff. Typical bakery (baked) products in accordance with the present invention include bread--such as loaves, rolls, buns, pizza bases etc.--pretzels, tortillas, cakes, cookies, biscuits, crackers etc. The preparation of foodstuffs such as bakery products is well know in the art. Dough production, for example, is described in example 2. The use of variant xylanases of the invention to alter the viscosity of a flour slurry in described in the example 5.

Starch Production

[0154] A variant xylanase of the invention may also be used in starch production from plant materials derived from cereals and tubers, such as potatoes.

Processing of Wood Pulp

[0155] A variant xylanase of the invention may also be used in processing wood pulp, for example in the preparation of paper.

[0156] As discussed above, we have shown that a major determinant of xylanase functionality is the presence of endogenous inhibitors in plant material. Consequently, although one method for altering xylanase functionality is to modify a xylanase to change its sensitivity to endogenous inhibitors, another method would be to vary the amount and/or type of inhibitor present in the plant material. Thus, the present invention also provides the use of a xylanase inhibitor to alter the functionality of a xylanase and consequently the use of a xylanase inhibitor in the methods of processing plant materials described above.

[0157] The present invention will now be further described with reference to the following examples which are intended to be illustrative only and non-limiting.

EXAMPLES

Example 1

Purification and Characterization of Wheat Endogenous Xylanase Inhibitor

[0158] 2 kg wheat flour (Danish reform, batch 99056) was extracted with water, using a flour:water ratio of 1:2, during 10 minutes of stirring. The soluble endogenous xylanase inhibitor was separated from the flour-water slurry by centrifugation. The extraction and centrifugation was performed at 4.degree. C. The inhibitor was purified from the water extract by the following chromatographic techniques and concentration techniques: HPLC-SEC, HPLC-CIEC, rotary evaporation, HPLC-HIC, HPLC-SEC and rotary evaporation. The xylanase inhibitor could be monitored and quantified during purification, using the following quantification method.

Inhibitor Quantification Method

[0159] 1 XIU (Xylanase Inhibitor Unit) is defined as the amount of inhibitor that decreases 1 TXU to 0.5 TXU under the conditions described below.

[0160] The xylanase used in this assay is Bacillus subtilis wild type xylanase.

[0161] 250 .mu.l xylanase solution containing 12 TXU/ml, approx. 100 .mu.l xylanase inhibitor solution and citric acid (0.1 M)--di-sodium-hydrogen phosphate (0.2 M) buffer, pH 5, to react a reaction volume of 1000 .mu.l is pre-incubated for 5 minutes at 40.degree. C. At t=5 minutes, 1 Xylazyme (Megazyme, Ireland) tablet is added to the reaction mixture. At t=15 minutes the reaction is terminated, by addition of 10 ml 2% TRIS/NaOH, pH 12. The solution is filtered and the absorbency of the supernatant is measured at 590 nm. By choosing several different concentrations of inhibitor in the above assay, it is possible to create a plot of OD versus inhibitor concentration. Using the slope (a) and intercept (b) from this plot and the concentration of the xylanase it is possible to calculate the amount of XIU in a given inhibitor solution (equation 1).

amount of XIU in solution=((b/2)/-a)/TXU Equation 1

[0162] From the endogenous xylanase inhibitor purification, the following inhibitor yield was recovered (table 1).

TABLE-US-00003 TABLE 1 Wheat endogenous xylanase inhibitor recovery after purification. Sample Amount XIU XIU, total Recovery, % Flour 2000 g 590/g 1.180.000 100 Purified inhibitor 90 ml 4658/ml 419.220 35.5

[0163] The inhibitor sample was pure and free from wheat endogenous xylanolytic activities.

Example 2

Fractionation and Reconstruction of Wheat Flour Free of Xylanase Inhibitor and Xylanases Functionality in this Flour as a Function of Added Xylanase Inhibitor

Flour Fractionation and Reconstitution

[0164] The flour used was: Danish Reform flour, batch No 99056. The fractionation, inhibitor inactivation and reconstitution were as follows:

[0165] A simple dough was made by mixing 1600 gram flour, with optimal water addition, according to a baker's absorption at 500 BU and mixing time according to Farinograph results. This resulted in 2512 gram dough. The gluten was manually washed out from the dough, using a water dough ratio of approx. 5:1. The water used was pre-chilled to 4.degree. C. to prevent further enzyme activity in the dough. The resulting wash-water contained the soluble proteins (including the xylanase inhibitor), lipids, non-starch polysaccharides and starch. The starch and other non-soluble components were separated from the wash-water by centrifugation (5000 g, 10 minutes, 10.degree. C.). To inactivate the endogenous xylanase inhibitor in the wash-water, the supernatant from the centrifugation was boiled for three minutes using a heat-evaporator.

[0166] All three fractions (gluten, starch and solubles) were frozen in flasks and placed in a freeze dryer. After drying, the fractions were weighed, grounded using a mortar and pestle, coffee mill and sieved through a 250 .mu.m sieve. All fractions were weighed again and flour was reconstituted, based on the ratios obtained after fractionation.

Enzymes

[0167] The xylanases listed in table 2 have been used in the study. The xylanases are purified, meaning no other xylonolytic activity is present in the sample.

TABLE-US-00004 TABLE 2 Xylanases used in the study and activity, TXU. ID Origin TXU B. sub B. subtilis. 5100 A. nig A. niger 8800

Xylanase Assay (Endo-D-1,4-Xylanase Activity)

[0168] Xylanase samples are diluted in citric acid (0.1 M)--di-sodium-hydrogen phosphate (0.2 M) buffer, pH 5.0, to obtain approx. OD=0.7 in the final assay. Three dilutions of the sample and an internal standard with a defined activity are thermostated for 5 minutes at 40.degree. C. At time=5 minutes, 1 Xylazyme tab (crosslinked, dyed xylan substrate) is added to the enzyme solution. At time=15 minutes (or in some cases longer, depending on the xylanase activity present in the sample) the reaction is terminated, by adding 10 ml of 2% TRIS. The reaction mixture is centrifuged and the OD of the supernatant is measured at 590 nm. Taking into account the dilutions and the amount of xylanase, the activity (TXU, Total-Xylanase-Units) of the sample can be calculated relative to the standard.

Baking Trials

[0169] Baking trials were done with (1.44.times.initial inhibitor level in Danish Reform flour, batch No 99056) and without addition of purified endogenous xylanase inhibitor to the reconstituted flour, respectively. The baking trials were done using the xylanases listed in table 2 and the compositions listed in table 3.

TABLE-US-00005 TABLE 3 Composition of dough made within the baking trials. Dough No ID TXU Inh. add, XIU/50 g 1 Control 0 0 2 B. sub 7500 0 3 A. nig 7500 0 4 B. sub 7500 850 5 A. nig 7500 850 6 Control 0 850

Dough Analysis

[0170] The dough were analysed with respect to:

Stickiness

[0171] Dough stickiness was measured on a TX-XT2 system (Stable Micro Systems) using a SMS Dough Stickiness Cell according to the method described by Chen And Hoseney (Lebensmittel Wiss u.--Technol., 28, 467-473. 1995).

Viscosity Analysis of Dough Liquid

[0172] The viscosity of extracted dough liquid was measured using a Brookfield viscosimeter after extraction.

Pentosan Analysis of Dough Liquid

[0173] Solubilised pentosan was measured in the dough liquid using the method of Rouau and Surget (Carbohydrate polymers, 24, 123-132, 1994).

Results

Flour Fractionation and Reconstitution

[0174] The fractionation and reconstitution of the dough resulted in 168.15 grams of freeze dried gluten, 111.13 grams of freeze dried soluble fraction and 1143.56 grams of freeze dried starch.

Inhibitor Quantification in Flour

[0175] Using the inhibitor quantification method, the inhibitor level in the 99056 flour and the reconstituted flour could be detected. The results from these analyses are listed in table 4.

TABLE-US-00006 TABLE 4 Results from inhibitor quantification in native flour (99056) and reconstituted flour. Inhibitor concentration, Flour XIU/g flour 99056 590 Reconstituted flour 42

[0176] Comparing the inhibitor level in the two portions of flour a 93% (100-(42XIU/590XIU).times.100%)) decrease of inhibitor level in the reconstituted flour is shown.

Baking Trials

[0177] The results from the baking trial are listed in tables 5 and 6.

TABLE-US-00007 TABLE 5 Data from baking trials with reconstituted flour, xylanase and +/-xylanase inhibitor addition. Std. dev., % represents the standard deviation over two days of baking. Inh., Avg. spec. vol, Std. ID TXU XIU/50 g ml/gram dev., % Control 0 42 3.04 4.06 B. sub 7500 42 3.23 12.51 A. nig. 7500 42 3.44 5.24 B. sub 7500 850 3.22 4.26 A. nig. 7500 850 3.38 0.70 Control 0 850 2.94 0.05

[0178] The standard deviation shown in table 5 reflects the dough handling properties of the tested dough. The dough made without the endogenous xylanase inhibitor (42 XIU), were very difficult to handle. The standard deviation for these doughs are in the area of 3 to 12.5%. Compared to the dough with the inhibitor added, this is quite high. If these standard deviations are compared with the actual changes in the bread volume, it can be seen that the figures are approximately the same value. This means that we can not conclude anything about the absence of the inhibitor's influence on the bread volume. If we look at the dough made with addition of the endogenous xylanase inhibitor (850 XIU) in table 5, we can see that we were able to produce bread from the reconstituted flour in a reproducible way over a two day period. The standard deviation was within the area of 0.05 to 4.2%, which is acceptable. From table 6 it can be seen, that the xylanases all increased the volume of the baked bread.

TABLE-US-00008 TABLE 6 Volume increase in bread baked from reconstituted flour as a function of xylanase and xylanase inhibitor addition. Volume Avg. spec. increase as Inh., vol, function of ID TXU XIU/50 g ml/gram xylanase, % Control 0 42 3.04 0.0 B. sub 7500 42 3.23 6.2 A. nig. 7500 42 3.44 13.3 B. sub 7500 850 3.22 9.7 A. nig. 7500 850 3.38 15.0 Control 0 850 2.94 0.0

[0179] What can be deduced from table 5 and table 6, is that the absence of the xylanase inhibitor in the flour made the handling of the dough very difficult. Therefore, what may seem as a positive response in volume by addition of inhibitor in table 6, probably can be explained by the high standard deviation in the dough lacking the inhibitor, due to difficult handling properties. Furthermore, it can be concluded that all the xylanases tested increased the bread volume significantly compared to the blank control.

Stickiness

[0180] The same dough, that was used for the baking trials, was used for stickiness measurements. The results are listed in table 7.

TABLE-US-00009 TABLE 7 Data representing stickiness as a function of time, xylanase and xylanase inhibitor addition to reconstituted flour. Avg. stickiness Avg. stickiness Inh., after 10 min, after 60 min, ID TXU XIU/50 g g .times. s g .times. s Control 0 42 4.71 4.79 B. sub. 7500 42 12.20 13.39 A. nig. 7500 42 9.22 12.58 B. sub. 7500 850 2.51 3.66 A. nig. 7500 850 5.24 6.45 Control 0 850 4.10 4.15

[0181] The results in table 7 clearly indicate the influence of the inhibitor that was observed in the experiment. The dough with a low level of xylanase inhibitor in combination with xylanase, was very difficult to handle and mould. However, when the inhibitor was added, the dough became dry and very easy to handle. As can be seen from table 7, addition of the 990202 xylanase in combination with the inhibitor decreased the stickiness. The dough became drier.

[0182] Table 7 also shows that there is only a small effect of time on the stickiness. It seems that the xylanases act very rapidly. Within the first 10 minutes most of the arabinoxylan is modified when the first xylanase (B. sub) is added. The second xylanase tested (A. nig), seems to act less rapidly. A function of time can easily be observed using this xylanase. This is also the xylanase that shows the least effect as a function of inhibitor level when analysed on stickiness.

Dough Viscosity

[0183] The dough viscosity and the pentosan analysis results were obtained from the same extraction of dough prepared from reconstituted flour added xylanase and xylanase inhibitor. This dough was analysed after two proofing times, 30 and 120 minutes.

[0184] The results of the viscosity analysis are presented in table 8.

TABLE-US-00010 TABLE 8 Data representing dough liquid viscosity as a function of time, xylanase and xylanase inhibitor addition to reconstituted flour. Avg. dough Inh., viscosity, Avg. dough viscosity, ID TXU XIU/50 g cP, 30 min proofing cP, 120 min proofing Control 0 42 5.21 5.56 B. sub. 7500 42 5.07 4.55 A. nig. 7500 42 5.78 4.14 B. sub. 7500 850 9.03 11.09 A. nig. 7500 850 8.44 8.55 Control 0 850 5.96 6.95

[0185] As can be seen from table 8 the inhibitor has a significant effect on the functionality of the xylanases. Without addition of the inhibitor, the arabinoxylan is being de-polymerised to Low Molecular Weight (LMW) arabinoxylan with a low viscosity. Addition of inhibitor prevents this very extensive de-polymerisation of the arabinoxylan.

Pentosan Analysis of Dough Liquid

[0186] The results from the pentosan (arabinoxylan) analysis of the dough liquid are presented in table 9.

TABLE-US-00011 TABLE 9 Data representing pentosan solubilisation as a function of time, xylanase and xylanase inhibitor addition to reconstituted flour. Inh., Avg. Pentosan, %, Avg. Pentosan, %, ID TXU XIU/50 g 30 min proofing 120 min proofing Control 0 42 0.387 0.458 B. sub. 7500 42 0.766 0.819 A. nig. 7500 42 0.719 0.798 B. sub. 7500 850 0.410 0.544 A. nig. 7500 850 0.560 0.673 Control 0 850 0.400 0.528

[0187] As can be seen from the results in table 9, the addition of endogenous xylanase inhibitor decreased the solubilisation of the arabinoxylan. When evaluated after 30 minutes proofing time, the amount of arabinoxylan solubilised in absence of the inhibitor is almost twice the amount as in presence of the inhibitor. Calculated on the basis of the relating control samples, the solubilisation is much higher in absence of the inhibitor, as illustrated in the following example:

(0.766-0.387)/(0.410-0.400)=37.9 times higher solubilisation

[0188] The above example was calculated on basis of solubilisation of arabinoxylan using the Bacillus xylanase, 30 minutes proofing and +/-inhibitor.

Example 3

Site-Directed Mutagenesis on Xylanases

[0189] Specific mutants of Bacillus subtilis xylanase may be obtained by site directed mutagenesis of the wild type enzyme, by the use of any of a number of commercially available mutagenesis kits. An example of how to obtain the D11F mutant using the Quick Exchange kit, available from Stratagene Cloning Systems, 11011 North Torrey Pines Road, La Jolla, Calif. 92037, USA is given below:

[0190] The DNA sequence encoding Bacillus subtilis xylanase A has been published by Paice et al., 1986.

[0191] The sequence of the coding region is as follows, with the sequence encoding the mature part of the protein shown in capitals: (SEQ ID NO: 10)

TABLE-US-00012 catatgtttaagtttaaaaagaatttcttagttggattatcggcagcttt aatgagtattagcttgttttcggcaaccgcctctgcaGCTAGCACAGACTA CTGGCAAAATTGGACTGATGGGGGCGGTATAGTAAACGCTGTCAATGGGT CTGGCGGGAATTACAGTGTTAATTGGTCTAATACCGGAAATTTTGTTGTT GGTAAAGGTTGGACTACAGGTTCGCCATTTAGGACGATAAACTATAATGC CGGAGTTTGGGCGCCGAATGGCAATGGATATTTAACTTTATATGGTTGGA CGAGATCACCTCTCATAGAATATTATGTAGTGGATTCATGGGGTACTTAT AGACCTACTGGAACGTATAAAGGTACTGTAAAAAGTGATGGGGGTACATA TGACATATATACAACTACACGTTATAACGCACCTTCCATTGATGGCGATC GCACTACTTTTACGCAGTACTGGAGTGTTCGCCAGTCGAAGAGACCAACC GGAAGCAACGCTACAATCACTTTCAGCAATCATGTGAACGCATGGAAGAG CCATGGAATGAATCTGGGCAGTAATTGGGCTTACCAAGTCATGGCGACAG AAGGATATCAAAGTAGTGGAAGTTCTAACGTAACAGTGTGGTAA

[0192] The part of the gene encoding the mature part of the wild type enzyme may be expressed intracellularly in E. coli by methods well known to people skilled in the art of molecular biology. For example: [0193] 1. Generating a copy of the capitalised part of the above described gene by use of the Polymerase Chain Reaction (PCR) with an added Nde1 restriction enzyme site (CATATG) before the GCTAGCACA and an added HindIII restriction site (AAGCTT) after the GTGTGGTAA. [0194] 2. Inserting the resultant modified copy of the gene by use of the above mentioned enzymes into the expression vector pET24a(+), which can be obtained from Novagen, Inc. 601 Science Drive, Madison, Wis. 53711, USA. [0195] 3. Transforming into a suitable E. coli strain and expression by fermentation as described by the vendor of pET24a(+).

[0196] Our D11F mutant enzyme may be obtained by using the "Quick Exchange" mutagenesis kit according to the manufacturer, and using the above described Bacillus subtilis wild type xylanase-pET24a(+) construct and the following PCR mutagenesis primers:

TABLE-US-00013 Sense primer: (SEQ ID NO: 12) CTACTGGCAAAATTGGACTTTTGGAGGAGGTATAGTAAACGCTG Antisense primer: (SEQ ID NO: 13) CAGCGTTTACTATACCTCCTCCAAAAGTCCAATTTTGCCAGTAG

[0197] The mutant enzyme is expressed and purified using the same protocols as for the wild type enzyme.

Example 4

Inhibition Studies of Xylanase Mutants

[0198] Xylanase mutants expressed in E. coli (see Example 3) were fermented and purified (meaning no other xylanolytic activity was present in the purified preparation) using a de-salting step and a cation exchange chromatography step.

[0199] These pure xylanase mutant preparations were diluted to 12 TXU/ml using 0.1 M citric acid-0.2 M di-sodium-hydrogen phosphate, pH 5.0 and used in the following assay.

[0200] A stable inhibitor preparation was made according to the protocol described in Example 1. This stable inhibitor preparation is used as stock for all xylanase-xylanase inhibitor studies. Using the inhibitor quantification method described in example 1, the inhibitor preparation was analysed to contain 126 XIU/ml.

Assay

[0201] To 250 .mu.l diluted xylanase mutant preparations, are added 0, 10, 25, 50 or 100 .mu.l inhibitor preparation, respectively. To these inhibitor-xylanase mixtures were added 0.1 M citric acid-0.2 M di-sodium-hydrogen phosphate, pH 5.0 making the end-volume 1000 .mu.l. These reaction mixtures were pre-incubated for 5 minutes at 40.degree. C. Hereafter 1 xylazyme tablet (Megazyme, Ireland) were added to all inhibitor-xylanase mixtures. After 10 minutes of incubation at 40.degree. C., the reactions were terminated, by adding 10 ml 2% Tris/NaOH, pH 12.0. The mixtures were centrifuged and the liberated blue colour from the substrate was measured at 590 nm.

[0202] The results are presented in table 10.

TABLE-US-00014 TABLE 10 Relative inhibition of xylanase mutants and parent xylanase (here wildtype enzyme) as a function of xylanase inhibitor. Mutant ID 0 1.26 3.15 6.3 12.6 Relative inhibition, % Wildtype 100 77 48 29 23 D11Y 100 120 114 126 124 D11N 100 93 72 53 32 D11F 100 114 119 116 115 D11K 100 109 112 113 116 D11S 100 98 81 60 38 D11W 100 101 88 70 50 G34D 100 94 83 70 53 G34F 100 76 53 34 29 G34T 100 99 99 93 86 Y113A 100 96 80 62 43 Y113D 100 96 81 63 45 Y113K 100 103 85 63 47 N114A 100 80 49 28 22 N114D 100 84 57 39 29 N114F 100 84 54 39 34 N114K 100 87 56 33 24 D121N 100 80 36 16 14 D121K 100 104 95 85 75 D121F 100 101 89 72 60 D121A 100 81 50 27 21 R122D 100 85 59 41 28 R122F 100 93 74 58 58 R122A 100 78 46 33 26 Q175E 100 87 59 40 31 Q175S 100 88 59 30 19 Q175L 100 78 42 25 23 G12F 100 110 106 100 92 G13F 100 104 95 87 84 I15K 100 84 47 28 23 N32K 100 82 42 19 14 G120K 100 85 52 29 22 G120D 100 84 47 24 18 G120F 100 71 35 18 15 G120Y 100 81 40 18 16 G120N 100 84 49 29 23 D119K 100 94 67 40 26 D119Y 100 87 50 28 22 D119N 100 91 74 44 22 T123K 100 80 46 30 25 T123Y 100 80 47 28 27 T123D 100 83 36 20 17 T124K 100 110 92 73 57 T124Y 100 101 76 49 33 T124D 100 87 52 32 25 N17K 100 88 48 31 26 N17Y 100 79 42 23 19 N17D 100 90 81 50 22 N29K 100 83 50 30 23 N29Y 100 85 49 30 24 N29D 100 74 44 26 20 S31K 100 77 42 23 23 S31Y 100 83 50 27 22 S31D 100 79 52 30 24 D11F/R122D 100 109 111 110 109 D11F/G34D 100 104 106 103 104

[0203] From the results in table 10, it can be seen the xylanase mutants D11Y, D11F, D11K, D11F/R122D and D11F/G34D are uninhibited by the wheat endogenous xylanase inhibitor. These xylanase mutants would be expected to act more aggressively/specifically on the soluble arabinoxylan, compared to the other xylanase mutants or other xylanases. They would therefore be superior in applications where a decrease in viscosity (as a function of HMW arabinoxylan) is wanted.

Example 5

Functionality Studies of Xylanase Mutants

[0204] Xylanase mutants expressed in E. Coli (see Example 3) were fermented and purified (meaning no other xylanolytic activity were present in the purified preparation).

[0205] These pure xylanase mutant preparations were diluted to 400 TXU/ml using water and used in the following assay.

Assay

[0206] 200 ml 30% (w/w) flour slurry was made using water (thermostated to 25.degree. C.), by stirring for 5 minutes. 60.0 ml of this flour slurry is poured into a Ford-cup, and the time for drainage of 50.0 ml is measured. This measurement is the blank measurement. The 60.0 ml flour slurry is poured back and 1000 .mu.l diluted xylanase mutant preparation is added to the flour slurry under stirring. After 2, 5, 10 and 20 minutes, 60.0 ml is poured into the Ford-cup, and the drainage time for 50.0 ml is recorded. Each measurement were done in triplicate.

[0207] The results are presented in table 11.

TABLE-US-00015 TABLE 11 Relative viscosity of flour slurry as a function of xylanase mutant and parent xylanase (here wild type xylanase) Incubation time, minutes 0 2 5 10 20 Relative viscosity Mutant ID change, % Wildtype 100 112 120 131 141 D11Y 100 97 93 83 75 D11N 100 112 125 130 136 D11F 100 93 87 78 69 D11K 100 105 95 88 78 D11S 100 102 110 113 117 D11W 100 106 115 121 122 G34D 100 110 120 128 124 G34F 100 111 126 128 146 G34T 100 100 108 111 106 Y113A 100 118 129 130 124 Y113D 100 116 127 124 114 Y113K 100 118 123 121 115 N114A 100 117 128 127 131 N114D 100 125 144 162 170 N114F 100 113 119 131 150 N114K 100 119 129 141 147 D121N 100 104 103 106 104 D121K 100 122 132 141 162 D121F 100 107 117 128 147 D121A 100 101 102 103 107 R122D 100 120 119 124 115 R122F 100 127 144 150 160 R122A 100 123 138 144 153 Q175E 100 116 134 142 149 Q175S 100 110 113 121 129 Q175L 100 111 111 119 126 G12F 100 127 132 122 101 G13F 100 106 119 124 113 I15K 100 109 108 113 118 N32K 100 97 98 101 101 G120K 100 103 111 115 121 G120D 100 112 122 120 126 G120F 100 103 111 117 130 G120Y 100 106 106 108 126 G120N 100 119 123 130 141 D119K 100 118 119 127 125 D119Y 100 102 102 111 110 D119N 100 126 137 145 146 T123K 100 106 109 121 120 T123Y 100 101 106 108 116 T123D 100 113 123 125 126 T124K 100 117 131 128 127 T124Y 100 112 123 132 135 T124D 100 103 110 111 118 N17K 100 114 119 119 132 N17Y 100 102 102 108 108 N17D 100 120 131 135 143 N29K 100 98 100 100 104 N29Y 100 115 117 132 143 N29D 100 104 104 113 111 S31K 100 119 115 124 134 S31Y 100 110 118 122 137 S31D 100 99 103 109 110 D11F/R122D 100 91 89 82 77 D11F/G34D 100 96 93 84 80

Example 6

Site-Directed Mutation in the Active Site of Bacillus subtilis Xylanase A, does not Influence the xylanase:xylanase Inhibitor Interaction

[0208] A residue in the active site of the Bacillus subtilis wildtype xylanase A enzyme was altered by a site-directed mutation (see ex. 3) In the mutated residue (Y166F) a potential hydrogen bond is lost. The mutant xylanase, was expressed in E. coli, fermented and purified. Hereafter, the mutant was investigated for its interaction with the xylanase inhibitor (see example 4).

[0209] As can be seen below (table 12), the exchange of an amino acid in the active site, did surprisingly not have any effect on interactions with the xylanase inhibitor as compared to the Bacillus subtilis wildtype xylanase enzyme.

TABLE-US-00016 TABLE 12 Relative inhibition of Bacillus subtilis wildtype xylanase and the xylanase mutant Y166F. XIU/ml 0 1.26 3.15 6.3 12.6 Xylanase ID Relative inhibition, % Wildtype 100 75 40 24 20 Y166F 100 74 39 22 20

[0210] Hence, in summary the experiment described above shows a site-directed mutation in the active site of the Bacillus subtilis xylanase A, which mutation does not influence the xylanase's interactions with the xylanase inhibitor.

Example 7

Site-Directed Mutation in Family 11 Xylanases other than the Bacillus subtilis Xylanase A, Influencing the xylanase-xylanase Inhibitor Interactions

[0211] D19 residue of the Thermomyces lanuginosus xylanase A enzyme was mutated to F19 by site-directed mutagenesis. D19 corresponds to D11 residue in the Bacillus subtilis xylanase (SEQ ID NO. 1). Thermomyces lanuginosus xylanase A gene is described as SEQ ID NO. 9.

[0212] The primers for PCR construction of the D19F mutant may be the following:

TABLE-US-00017 Sense primer: (SEQ ID NO: 14) GGTTATTACTATTCCTGGTGGAGTTTTGGAGGAGCGCAGGCCACG Antisense primer: (SEQ ID NO: 15) CGTGGCCTGCGCTCCTCCAAAACTCCACCAGGAATAGTAATAACC

[0213] The obtained mutant xylanase (D19F), was expressed in E. coli, fermented and purified. Hereafter, the mutant and the Thermomyces lanuginosus wildtype xylanase A was investigated for to its interaction with the xylanase inhibitor (see example 4). As can be seen from the results in table 13, the D19F mutant of the Thermomyces lanuginosus xylanase A is significantly less inhibited by the xylanase inhibitor as compared to the Thermomyces lanuginosus wildtype xylanase A.

TABLE-US-00018 TABLE 13 Relative inhibition of Thermomyces lanoginosus wildtype xylanase A (TLX) and the Thermomyces lanoginosus mutant xylanase, D19F (D19F). XIU/ml 0 1.26 3.15 6.3 12.6 Xylanase ID Relativeinhibition, % TLX 100 45 24 17 14 D19F 100 73 38 24 20

[0214] Hence, in summary the experiment described above shows a site-directed mutation in the Thermomyces lanuginosus xylanase A. The results show that a mutation introducing a substitution of an amino acid on the surface of the xylanase molecule (analogue to the D11F in B. subtilis) changes the xylanase:xylanase inhibitor interactions. Thus, our invention (i.e. that surface residues control the level of inhibition of xylanase) holds true for xylanases that are homologous to the B. subtilis xylanase.

SUMMARY

[0215] In summary, the present invention provides a means for altering the sensitivity of a xylanase enzyme to a xylanase inhibitor.

[0216] All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

REFERENCES

[0217] Courtin, C., Roelants, A. and Delcour, J. (1999). Fractionation-reconstitution experiments provide insight into the role of endoxylanases in bread-making. Journal of Agricultural and Food Chemistry. 47. 1870-1877. [0218] D'Appolonia, B. L. and MacArthur, L. A. (1976). Comparison of bran and endosperm pentosans in immature and mature wheat. Cereal Chem. 53. 711-718. [0219] Debyser, W. and Delcour, J. A. (1998). Inhibitors of cellolytic, xylanolytic and .beta.-glucanolytic enzymes. WO 98/49278. [0220] Hazlewood, G. P. and Gelbert, H. J. (1993). Recombinant xylanases. PCT application. WO 93/25693. [0221] Ingelbrecht, J. A., Verwimp, T. and Delcour, J. A. (1999). Endoxylanases in durum wheat semolina processing: solubilisation of arabinoxylans, action of endogenous inhibitors and effects on rheological properties. J. Agri. Food Chem. [0222] Jacobsen, T. S., Heldt-Hansen, H. P., Kofod, L. V., Bagger, C. and Mullertz, A. (1995). Processing plant material with xylanase. PCT application. WO 95/23514. [0223] Kormelink, F. J. M. (1992). Characterisation and mode of action of xylanases and some accessory enzymes. Ph.D. Thesis, Agricultural University Wageningen, Holland (175 pp., English and Dutch summaries). [0224] McLauchlan, R., Garcia-Conesa, M. T., Williamson, G., Roza, M., Ravestein, P. and MacGregor, A. W. (1999a). A novel class of protein from wheat which inhibits xylanases. Biochem. J. 338. 441-446. [0225] McLauchlan, R, Flatman, R et al (1999) Poster Presentation from meeting at University of Newcastle (1999) April 11 h-April 17.sup.th. Xylanase inhibitors, a novel class of proteins from cereals.

[0226] Montgomery, R. and Smith, F. (1955). The Carbohydrates of the Gramineae. VIII. The constitution of a water soluble hemicellulose of the endosperm of wheat (Triticum vulgare). J. Am. Chem. Soc. 77. 3325-3328. [0227] Paice, M. G., Bourbonnais, R., Desrochers, M., Jurasek, L. and Yaguchi, M. (1986): A Xylanase Gene from Bacillus subtilis: Nucleotide Sequence and Comparison with B. pumilus Gene. Arch. Microbiol. 144, 201-206.) [0228] Rouau, X. (1993). Investigations into the effects of an enzyme preparation fro baking on wheat flour dough pentosans. J. Cereal Science. 18. 145-157. [0229] Rouau, X., El-Hayek, M-L. and Moreau, D. (1994). Effect of an enzyme preparation containing pentosanases on the bread-making quality of flour in relation to changes in pentosan properties. J. Cereal Science. 19. 259-272. [0230] Slade, L., Levine, H., Craig, S., Arciszewski, H. and Saunders, S. (1993). Enzyme treated low moisture content comestible products. U.S. Pat. No. 5,200,215 by Nabisco. [0231] Soerensen, J. F. and Sibbesen, O. (1999). Bacterial xylanase. UK A 9828599.2.

Sequence CWU 1

1

661185PRTBacillus subtilis 1Ala Ser Thr Asp Tyr Trp Gln Asn Trp Thr Asp Gly Gly Gly Ile Val1 5 10 15Asn Ala Val Asn Gly Ser Gly Gly Asn Tyr Ser Val Asn Trp Ser Asn 20 25 30Thr Gly Asn Phe Val Val Gly Lys Gly Trp Thr Thr Gly Ser Pro Phe 35 40 45Arg Thr Ile Asn Tyr Asn Ala Gly Val Trp Ala Pro Asn Gly Asn Gly 50 55 60Tyr Leu Thr Leu Tyr Gly Trp Thr Arg Ser Pro Leu Ile Glu Tyr Tyr65 70 75 80Val Val Asp Ser Trp Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly 85 90 95Thr Val Lys Ser Asp Gly Gly Thr Tyr Asp Ile Tyr Thr Thr Thr Arg 100 105 110Tyr Asn Ala Pro Ser Ile Asp Gly Asp Arg Thr Thr Phe Thr Gln Tyr 115 120 125Trp Ser Val Arg Gln Ser Lys Arg Pro Thr Gly Ser Asn Ala Thr Ile 130 135 140Thr Phe Ser Asn His Val Asn Ala Trp Lys Ser His Gly Met Asn Leu145 150 155 160Gly Ser Asn Trp Ala Tyr Gln Val Met Ala Thr Glu Gly Tyr Gln Ser 165 170 175Ser Gly Ser Ser Asn Val Thr Val Trp 180 185235PRTwheat 2Gly Ala Pro Val Ala Arg Ala Val Glu Ala Val Ala Pro Phe Gly Val1 5 10 15Cys Tyr Asp Thr Lys Thr Leu Gly Asn Asn Leu Gly Gly Tyr Ala Val 20 25 30Pro Asn Val 35317PRTWheat 3Lys Arg Leu Gly Phe Ser Arg Leu Pro His Phe Thr Gly Cys Gly Gly1 5 10 15Leu421PRTWheat 4Leu Pro Val Pro Ala Pro Val Thr Lys Asp Pro Ala Thr Ser Leu Tyr1 5 10 15Thr Ile Pro Phe His 20531PRTWheat 5Leu Leu Ala Ser Leu Pro Arg Gly Ser Thr Gly Val Ala Gly Leu Ala1 5 10 15Asn Ser Gly Leu Ala Leu Pro Ala Gln Val Ala Ser Ala Gln Lys 20 25 30624PRTWheat 6Gly Gly Ser Pro Ala His Tyr Ile Ser Ala Arg Phe Ile Glu Val Gly1 5 10 15Asp Thr Arg Val Pro Ser Val Glu 20713PRTWheat 7Val Asn Val Gly Val Leu Ala Ala Cys Ala Pro Ser Lys1 5 10841PRTWheat 8Val Ala Asn Arg Phe Leu Leu Cys Leu Pro Thr Gly Gly Pro Gly Val1 5 10 15Ala Ile Phe Gly Gly Gly Pro Val Pro Trp Pro Gln Phe Thr Gln Ser 20 25 30Met Pro Tyr Thr Leu Val Val Val Lys 35 409588DNAThermomyces lanuginosus 9atgcagacaa cccccaactc ggagggctgg cacgatggtt attactattc ctggtggagt 60gacggtggag cgcaggccac gtacaccaac ctggaaggcg gcacctacga gatcagctgg 120ggagatggcg gtaacctcgt cggtggaaag ggctggaacc ccggcctgaa cgcaagagcc 180atccactttg agggtgttta ccagccaaac ggcaacagct accttgcggt ctacggttgg 240acccgcaacc cgctggtcga gtattacatc gtcgagaact ttggcaccta tgatccttcc 300tccggtgcta ccgatctagg aactgtcgag tgcgacggta gcatctatcg actcggcaag 360accactcgcg tcaacgcacc tagcatcgac ggcacccaaa ccttcgacca atactggtcg 420gtccgccagg acaagcgcac cagcggtacc gtccagacgg gctgccactt cgacgcctgg 480gctcgcgctg gtttgaatgt caacggtgac cactactacc agatcgttgc aacggagggc 540tacttcagca gcggctatgc tcgcatcacc gttgctgacg tgggctaa 58810645DNABacillus subtilis 10catatgttta agtttaaaaa gaatttctta gttggattat cggcagcttt aatgagtatt 60agcttgtttt cggcaaccgc ctctgcagct agcacagact actggcaaaa ttggactgat 120gggggcggta tagtaaacgc tgtcaatggg tctggcggga attacagtgt taattggtct 180aataccggaa attttgttgt tggtaaaggt tggactacag gttcgccatt taggacgata 240aactataatg ccggagtttg ggcgccgaat ggcaatggat atttaacttt atatggttgg 300acgagatcac ctctcataga atattatgta gtggattcat ggggtactta tagacctact 360ggaacgtata aaggtactgt aaaaagtgat gggggtacat atgacatata tacaactaca 420cgttataacg caccttccat tgatggcgat cgcactactt ttacgcagta ctggagtgtt 480cgccagtcga agagaccaac cggaagcaac gctacaatca ctttcagcaa tcatgtgaac 540gcatggaaga gccatggaat gaatctgggc agtaattggg cttaccaagt catggcgaca 600gaaggatatc aaagtagtgg aagttctaac gtaacagtgt ggtaa 64511657DNAUnknownB. subtilis xylanase sequence with added restriction site 11catatgttta agtttaaaaa gaatttctta gttggattat cggcagcttt aatgagtatt 60agcttgtttt cggcaaccgc ctctgcacat atggctagca cagactactg gcaaaattgg 120actgatgggg gcggtatagt aaacgctgtc aatgggtctg gcgggaatta cagtgttaat 180tggtctaata ccggaaattt tgttgttggt aaaggttgga ctacaggttc gccatttagg 240acgataaact ataatgccgg agtttgggcg ccgaatggca atggatattt aactttatat 300ggttggacga gatcacctct catagaatat tatgtagtgg attcatgggg tacttataga 360cctactggaa cgtataaagg tactgtaaaa agtgatgggg gtacatatga catatataca 420actacacgtt ataacgcacc ttccattgat ggcgatcgca ctacttttac gcagtactgg 480agtgttcgcc agtcgaagag accaaccgga agcaacgcta caatcacttt cagcaatcat 540gtgaacgcat ggaagagcca tggaatgaat ctgggcagta attgggctta ccaagtcatg 600gcgacagaag gatatcaaag tagtggaagt tctaacgtaa cagtgtggta aaagctt 6571244DNAUnknownsense primer 12ctactggcaa aattggactt ttggaggagg tatagtaaac gctg 441344DNAUnknownAntisense primer 13cagcgtttac tatacctcct ccaaaagtcc aattttgcca gtag 441445DNAUnknownSense primer 14ggttattact attcctggtg gagttttgga ggagcgcagg ccacg 451545DNAUnknownAntisense primer 15cgtggcctgc gctcctccaa aactccacca ggaatagtaa taacc 4516213PRTBacillus subtilis 16Met Phe Lys Phe Lys Lys Asn Phe Leu Val Gly Leu Ser Ala Ala Leu1 5 10 15Met Ser Ile Ser Leu Phe Ser Ala Thr Ala Ser Ala Ala Ser Thr Asp 20 25 30Tyr Trp Gln Asn Trp Thr Asp Gly Gly Gly Ile Val Asn Ala Val Asn 35 40 45Gly Ser Gly Gly Asn Tyr Ser Val Asn Trp Ser Asn Thr Gly Asn Phe 50 55 60Val Val Gly Lys Gly Trp Thr Thr Gly Ser Pro Phe Arg Thr Ile Asn65 70 75 80Tyr Asn Ala Gly Val Trp Ala Pro Asn Gly Asn Gly Tyr Leu Thr Leu 85 90 95Tyr Gly Trp Thr Arg Ser Pro Leu Ile Glu Tyr Tyr Val Val Asp Ser 100 105 110Trp Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Thr Val Lys Ser 115 120 125Asp Gly Gly Thr Tyr Asp Ile Tyr Thr Thr Thr Arg Tyr Asn Ala Pro 130 135 140Ser Ile Asp Gly Asp Arg Thr Thr Phe Thr Gln Tyr Trp Ser Val Arg145 150 155 160Gln Ser Lys Arg Pro Thr Gly Ser Asn Ala Thr Ile Thr Phe Ser Asn 165 170 175His Val Asn Ala Trp Lys Ser His Gly Met Asn Leu Gly Ser Asn Trp 180 185 190Ala Tyr Gln Val Met Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser 195 200 205Asn Val Thr Val Trp 21017213PRTBacillus circulans 17Met Phe Lys Phe Lys Lys Asn Phe Leu Val Gly Leu Ser Ala Ala Leu1 5 10 15Met Ser Ile Ser Leu Phe Ser Ala Thr Ala Ser Ala Ala Ser Thr Asp 20 25 30Tyr Trp Gln Asn Trp Thr Asp Gly Gly Gly Ile Val Asn Ala Val Asn 35 40 45Gly Ser Gly Gly Asn Tyr Ser Val Asn Trp Ser Asn Thr Gly Asn Phe 50 55 60Val Val Gly Lys Gly Trp Thr Thr Gly Ser Pro Phe Arg Thr Ile Asn65 70 75 80Tyr Asn Ala Gly Val Trp Ala Pro Asn Gly Asn Gly Tyr Leu Thr Leu 85 90 95Tyr Gly Trp Thr Arg Ser Pro Leu Ile Glu Tyr Tyr Val Val Asp Ser 100 105 110Trp Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Thr Val Lys Ser 115 120 125Asp Gly Gly Thr Tyr Asp Ile Tyr Thr Thr Thr Arg Tyr Asn Ala Pro 130 135 140Ser Ile Asp Gly Asp Arg Thr Thr Phe Thr Gln Tyr Trp Ser Val Arg145 150 155 160Gln Ser Lys Arg Pro Thr Gly Ser Asn Ala Thr Ile Thr Phe Thr Asn 165 170 175His Val Asn Ala Trp Lys Ser His Gly Met Asn Leu Gly Ser Asn Trp 180 185 190Ala Tyr Gln Val Met Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser 195 200 205Asn Val Thr Val Trp 21018211PRTBacillus stearothermophilus 18Met Lys Leu Lys Lys Lys Met Leu Thr Leu Leu Leu Thr Ala Ser Met1 5 10 15Ser Phe Gly Leu Phe Gly Ala Thr Ser Ser Ala Ala Thr Asp Tyr Trp 20 25 30Gln Tyr Trp Thr Asp Gly Gly Gly Met Val Asn Ala Val Asn Gly Pro 35 40 45Gly Gly Asn Tyr Ser Val Thr Trp Gln Asn Thr Gly Asn Phe Val Val 50 55 60Gly Lys Gly Trp Thr Val Gly Ser Pro Asn Arg Val Ile Asn Tyr Asn65 70 75 80Ala Gly Ile Trp Glu Pro Ser Gly Asn Gly Tyr Leu Thr Leu Tyr Gly 85 90 95Trp Thr Arg Asn Ala Leu Ile Glu Tyr Tyr Val Val Asp Ser Trp Gly 100 105 110Thr Tyr Arg Ala Thr Gly Asn Tyr Glu Ser Gly Thr Val Asn Ser Asp 115 120 125Gly Gly Thr Tyr Asp Ile Tyr Thr Thr Met Arg Tyr Asn Ala Pro Ser 130 135 140Ile Asp Gly Thr Gln Thr Phe Gln Gln Phe Trp Ser Val Arg Gln Ser145 150 155 160Lys Arg Pro Thr Gly Ser Asn Val Ser Ile Thr Phe Ser Asn His Val 165 170 175Asn Ala Trp Arg Ser Lys Gly Met Asn Leu Gly Ser Ser Trp Ala Tyr 180 185 190Gln Val Leu Ala Thr Glu Gly Tyr Gln Ser Ser Gly Arg Ser Asn Val 195 200 205Thr Val Trp 21019211PRTA. caviae 19Met Phe Lys Phe Gly Lys Lys Leu Met Thr Val Val Leu Ala Ala Ser1 5 10 15Met Ser Phe Gly Val Phe Ala Ala Thr Ser Ser Ala Ala Thr Asp Tyr 20 25 30Trp Gln Asn Trp Thr Asp Gly Gly Gly Thr Val Asn Ala Val Asn Gly 35 40 45Ser Gly Gly Asn Tyr Ser Val Ser Trp Gln Asn Thr Gly Asn Phe Val 50 55 60Val Gly Lys Gly Trp Thr Tyr Gly Thr Pro Asn Arg Val Val Asn Tyr65 70 75 80Asn Ala Gly Val Phe Ala Pro Ser Gly Asn Gly Tyr Leu Thr Phe Tyr 85 90 95Gly Trp Thr Arg Asn Ala Leu Ile Glu Tyr Tyr Val Val Asp Ser Trp 100 105 110Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Thr Val Asn Ser Asp 115 120 125Gly Gly Thr Tyr Asp Ile Tyr Thr Thr Met Arg Tyr Asn Ala Pro Ser 130 135 140Ile Asp Gly Thr Gln Thr Phe Pro Gln Tyr Trp Ser Val Arg Gln Ser145 150 155 160Lys Arg Pro Thr Gly Val Asn Ser Thr Ile Thr Phe Ser Asn His Val 165 170 175Asn Ala Trp Pro Ser Lys Gly Met Tyr Leu Gly Asn Ser Trp Ser Tyr 180 185 190Gln Val Met Ala Thr Glu Gly Tyr Gln Ser Ser Gly Asn Ala Asn Val 195 200 205Thr Val Trp 21020221PRTC. carbonum 20Met Val Ser Phe Thr Ser Ile Ile Thr Ala Ala Val Ala Ala Thr Gly1 5 10 15Ala Leu Ala Ala Pro Ala Thr Asp Val Ser Leu Val Ala Arg Gln Asn 20 25 30Thr Pro Asn Gly Glu Gly Thr His Asn Gly Cys Phe Trp Ser Trp Trp 35 40 45Ser Asp Gly Gly Ala Arg Ala Thr Tyr Thr Asn Gly Ala Gly Gly Ser 50 55 60Tyr Ser Val Ser Trp Gly Ser Gly Gly Asn Leu Val Gly Gly Lys Gly65 70 75 80Trp Asn Pro Gly Thr Ala Arg Thr Ile Thr Tyr Ser Gly Thr Tyr Asn 85 90 95Tyr Asn Gly Asn Ser Tyr Leu Ala Val Tyr Gly Trp Thr Arg Asn Pro 100 105 110Leu Val Glu Tyr Tyr Val Val Glu Asn Phe Gly Thr Tyr Asp Pro Ser 115 120 125Ser Gln Ser Gln Asn Lys Gly Thr Val Thr Ser Asp Gly Ser Ser Tyr 130 135 140Lys Ile Ala Gln Ser Thr Arg Thr Asn Gln Pro Ser Ile Asp Gly Thr145 150 155 160Arg Thr Phe Gln Gln Tyr Trp Ser Val Arg Gln Asn Lys Arg Ser Ser 165 170 175Gly Ser Val Asn Met Lys Thr His Phe Asp Ala Trp Ala Ser Lys Gly 180 185 190Met Asn Leu Gly Gln His Tyr Tyr Gln Ile Val Ala Thr Glu Gly Tyr 195 200 205Phe Ser Thr Gly Asn Ala Gln Ile Thr Val Asn Cys Pro 210 215 22021227PRTH. turcicum 21Met Val Ser Phe Thr Ser Ile Ile Thr Ala Ala Val Ala Ala Thr Gly1 5 10 15Ala Leu Ala Ala Pro Ala Thr Asp Ile Ala Ala Arg Ala Pro Ser Asp 20 25 30Leu Val Ala Arg Gln Ser Thr Pro Asn Gly Glu Gly Thr His Asn Gly 35 40 45Cys Phe Tyr Ser Trp Trp Ser Asp Gly Gly Ala Arg Ala Thr Tyr Thr 50 55 60Asn Gly Ala Gly Gly Ser Tyr Ser Val Ser Trp Gly Thr Gly Gly Asn65 70 75 80Leu Val Gly Gly Lys Gly Trp Asn Pro Gly Thr Ala Arg Thr Ile Thr 85 90 95Tyr Ser Gly Gln Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Ala Ile Tyr 100 105 110Gly Trp Thr Arg Asn Pro Leu Val Glu Tyr Tyr Val Val Glu Asn Phe 115 120 125Gly Thr Tyr Asp Pro Ser Ser Gln Ala Gln Asn Lys Gly Thr Val Thr 130 135 140Ser Asp Gly Ser Ser Tyr Lys Ile Ala Gln Ser Thr Arg Thr Asn Gln145 150 155 160Pro Ser Ile Asp Gly Thr Arg Thr Phe Gln Gln Tyr Trp Ser Val Arg 165 170 175Gln Asn Lys Arg Ser Ser Gly Ser Val Asn Met Lys Thr His Phe Asp 180 185 190Ala Trp Ala Ser Lys Gly Met Asn Leu Gly Ser His Tyr Tyr Gln Ile 195 200 205Val Ala Thr Glu Gly Tyr Phe Ser Ser Gly Ser Ala Ser Ile Thr Val 210 215 220Asn Cys Pro22522227PRTA. pisi 22Met Val Ser Phe Thr Ser Ile Phe Thr Ala Ala Val Ala Ala Thr Gly1 5 10 15Ala Leu Ala Val Pro Val Thr Asp Leu Ala Thr Arg Ser Leu Gly Ala 20 25 30Leu Thr Ala Arg Ala Gly Thr Pro Ser Ser Gln Gly Thr His Asn Gly 35 40 45Cys Phe Tyr Ser Trp Trp Thr Asp Gly Gly Ala Gln Ala Thr Tyr Thr 50 55 60Asn Gly Ala Gly Gly Ser Tyr Ser Val Asn Trp Lys Thr Gly Gly Asn65 70 75 80Leu Val Gly Gly Lys Gly Trp Asn Pro Gly Ala Ala Arg Thr Ile Thr 85 90 95Tyr Ser Gly Thr Tyr Ser Pro Ser Gly Asn Ser Tyr Leu Ala Val Tyr 100 105 110Gly Trp Thr Arg Asn Pro Leu Ile Glu Tyr Tyr Val Val Glu Asn Phe 115 120 125Gly Thr Tyr Asp Pro Ser Ser Gln Ala Thr Val Lys Gly Ser Val Thr 130 135 140Ala Asp Gly Ser Ser Tyr Lys Ile Ala Gln Thr Gln Arg Thr Asn Gln145 150 155 160Pro Ser Ile Asp Gly Thr Gln Thr Phe Gln Gln Tyr Trp Ser Val Arg 165 170 175Gln Asn Lys Arg Ser Ser Gly Ser Val Asn Met Lys Thr His Phe Asp 180 185 190Ala Trp Ala Ala Lys Gly Met Lys Leu Gly Thr His Asn Tyr Gln Ile 195 200 205Val Ala Thr Glu Gly Tyr Phe Ser Ser Gly Ser Ala Gln Ile Thr Val 210 215 220Asn Cys Ala22523201PRTS. commune 23Ala Ala Ser Gly Thr Pro Ser Ser Thr Gly Thr Asp Gly Gly Tyr Tyr1 5 10 15Tyr Ser Trp Trp Thr Asp Gly Ala Gly Asp Ala Thr Tyr Gln Asn Asn 20 25 30Gly Gly Gly Ser Tyr Thr Leu Thr Trp Ser Gly Asn Asn Gly Asn Leu 35 40 45Val Gly Gly Lys Gly Trp Asn Pro Gly Ala Ala Ser Arg Ser Ile Ser 50 55 60Tyr Ser Gly Thr Tyr Gln Pro Asn Gly Asn Ser Tyr Leu Ser Val Tyr65 70 75 80Gly Trp Thr Arg Ser Ser Leu Ile Glu Tyr Tyr Ile Val Glu Ser Tyr 85 90 95Gly Ser Tyr Asp Pro Ser Ser Ala Ala Ser His Lys Gly Ser Val Thr 100 105 110Cys Asn Gly Ala Thr Tyr Asp Ile Leu Ser Thr Trp Arg Tyr Asn Ala 115 120 125Pro Ser Ile Asp Gly Thr Gln Thr Phe Glu Gln Phe Trp Ser Val Arg 130 135 140Asn Pro Lys Lys Ala Pro Gly Gly Ser Ile Ser Gly Thr Val Asp Val145 150 155

160Gln Cys His Phe Asp Ala Trp Lys Gly Leu Gly Met Asn Leu Gly Ser 165 170 175Glu His Asn Tyr Gln Ile Val Ala Thr Glu Gly Tyr Gln Ser Ser Gly 180 185 190Thr Ala Thr Ile Thr Val Thr Ala Ser 195 20024225PRTT. lanuginosus 24Met Val Gly Phe Thr Pro Val Ala Leu Ala Ala Leu Ala Ala Thr Gly1 5 10 15Ala Leu Ala Phe Pro Ala Gly Asn Ala Thr Glu Leu Glu Lys Arg Gln 20 25 30Thr Thr Pro Asn Ser Glu Gly Trp His Asp Gly Tyr Tyr Tyr Ser Trp 35 40 45Trp Ser Asp Gly Gly Ala Gln Ala Thr Tyr Thr Asn Leu Glu Gly Gly 50 55 60Thr Tyr Glu Ile Ser Trp Gly Asp Gly Gly Asn Leu Val Gly Gly Lys65 70 75 80Gly Trp Asn Pro Gly Leu Asn Ala Arg Ala Ile His Phe Glu Gly Val 85 90 95Tyr Gln Pro Asn Gly Asn Ser Tyr Leu Ala Val Tyr Gly Trp Thr Arg 100 105 110Asn Pro Leu Val Glu Tyr Tyr Ile Val Glu Asn Phe Gly Thr Tyr Asp 115 120 125Pro Ser Ser Gly Ala Thr Asp Leu Gly Thr Val Glu Cys Asp Gly Ser 130 135 140Ile Tyr Arg Leu Gly Lys Thr Thr Arg Val Asn Ala Pro Ser Ile Asp145 150 155 160Gly Thr Gln Thr Phe Asp Gln Tyr Trp Ser Val Arg Gln Asp Lys Arg 165 170 175Thr Ser Gly Thr Val Gln Thr Gly Cys His Phe Asp Ala Trp Ala Arg 180 185 190Ala Gly Leu Asn Val Asn Gly Asp His Tyr Tyr Gln Ile Val Ala Thr 195 200 205Glu Gly Tyr Phe Ser Ser Gly Tyr Ala Arg Ile Thr Val Ala Asp Val 210 215 220Gly22525231PRTC. carbonum 25Met Val Ser Phe Lys Ser Leu Leu Leu Ala Ala Val Ala Thr Thr Ser1 5 10 15Val Leu Ala Ala Pro Phe Asp Phe Leu Arg Glu Arg Asp Asp Val Asn 20 25 30Ala Thr Ala Leu Leu Glu Lys Arg Gln Ser Thr Pro Ser Ala Glu Gly 35 40 45Tyr His Asn Gly Tyr Phe Tyr Ser Trp Trp Thr Asp Gly Gly Gly Ser 50 55 60Ala Gln Tyr Thr Met Gly Glu Gly Ser Arg Tyr Ser Val Thr Trp Arg65 70 75 80Asn Thr Gly Asn Phe Val Gly Gly Lys Gly Trp Asn Pro Gly Ser Gly 85 90 95Arg Val Ile Asn Tyr Gly Gly Ala Phe Asn Pro Gln Gly Asn Gly Tyr 100 105 110Leu Ala Val Tyr Gly Trp Thr Arg Asn Pro Leu Val Glu Tyr Tyr Val 115 120 125Ile Glu Ser Tyr Gly Thr Tyr Asn Pro Ser Ser Gly Ala Gln Ile Lys 130 135 140Gly Ser Phe Gln Thr Asp Gly Gly Thr Tyr Asn Val Ala Val Ser Thr145 150 155 160Arg Tyr Asn Gln Pro Ser Ile Asp Gly Thr Arg Thr Phe Gln Gln Tyr 165 170 175Trp Ser Val Arg Thr Gln Lys Arg Val Gly Gly Ser Val Asn Met Gln 180 185 190Asn His Phe Asn Ala Trp Ser Arg Tyr Gly Leu Asn Leu Gly Gln His 195 200 205Tyr Tyr Gln Ile Val Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser 210 215 220Asp Ile Tyr Val Gln Thr Gln225 23026231PRTC. sativus 26Met Val Ser Phe Lys Ser Leu Leu Leu Ala Ala Val Ala Thr Thr Ser1 5 10 15Val Leu Ala Ala Pro Phe Asp Phe Leu Arg Glu Arg Asp Asp Gly Asn 20 25 30Ala Thr Ala Leu Leu Glu Lys Arg Gln Ser Thr Pro Ser Ser Glu Gly 35 40 45Tyr His Asn Gly Tyr Phe Tyr Ser Trp Trp Thr Asp Gly Gly Gly Ser 50 55 60Ala Gln Tyr Thr Met Gly Glu Gly Ser Arg Tyr Ser Val Thr Trp Arg65 70 75 80Asn Thr Gly Asn Phe Val Gly Gly Lys Gly Trp Asn Pro Gly Thr Gly 85 90 95Arg Val Ile Asn Tyr Gly Gly Ala Phe Asn Pro Gln Gly Asn Gly Tyr 100 105 110Leu Ala Val Tyr Gly Trp Thr Arg Asn Pro Leu Val Glu Tyr Tyr Val 115 120 125Ile Glu Ser Tyr Gly Thr Tyr Asn Pro Ser Ser Gly Ala Gln Val Lys 130 135 140Gly Ser Phe Gln Thr Asp Gly Gly Thr Tyr Asn Val Ala Val Ser Thr145 150 155 160Arg Tyr Asn Gln Pro Ser Ile Asp Gly Thr Arg Thr Phe Gln Gln Tyr 165 170 175Trp Ser Val Arg Gln Gln Lys Arg Val Gly Gly Ser Val Asn Met Gln 180 185 190Asn His Phe Asn Ala Trp Ser Arg Tyr Gly Leu Asn Leu Gly Gln His 195 200 205Tyr Tyr Gln Ile Val Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser 210 215 220Asp Ile Tyr Val Gln Thr Gln225 23027227PRTH. insolens 27Met Val Ser Leu Lys Ser Val Leu Ala Ala Ala Thr Ala Val Ser Ser1 5 10 15Ala Ile Ala Ala Pro Phe Asp Phe Val Pro Arg Asp Asn Ser Thr Ala 20 25 30Leu Gln Ala Arg Gln Val Thr Pro Asn Ala Glu Gly Trp His Asn Gly 35 40 45Tyr Phe Tyr Ser Trp Trp Ser Asp Gly Gly Gly Gln Val Gln Tyr Thr 50 55 60Asn Leu Glu Gly Ser Arg Tyr Gln Val Arg Trp Arg Asn Thr Gly Asn65 70 75 80Phe Val Gly Gly Lys Gly Trp Asn Pro Gly Thr Gly Arg Thr Ile Asn 85 90 95Tyr Gly Gly Tyr Phe Asn Pro Gln Gly Asn Gly Tyr Leu Ala Val Tyr 100 105 110Gly Trp Thr Arg Asn Pro Leu Val Glu Tyr Tyr Val Ile Glu Ser Tyr 115 120 125Gly Thr Tyr Asn Pro Gly Ser Gln Ala Gln Tyr Lys Gly Thr Phe Tyr 130 135 140Thr Asp Gly Asp Gln Tyr Asp Ile Phe Val Ser Thr Arg Tyr Asn Gln145 150 155 160Pro Ser Ile Asp Gly Thr Arg Thr Phe Gln Gln Tyr Trp Ser Ile Arg 165 170 175Lys Asn Lys Arg Val Gly Gly Ser Val Asn Met Gln Asn His Phe Asn 180 185 190Ala Trp Gln Gln His Gly Met Pro Leu Gly Gln His Tyr Tyr Gln Val 195 200 205Val Ala Thr Glu Gly Tyr Gln Ser Ser Gly Glu Ser Asp Ile Tyr Val 210 215 220Gln Thr His22528233PRTM. grisea 28Met Val Ser Phe Thr Ser Ile Val Thr Ala Val Val Ala Leu Ala Gly1 5 10 15Ser Ala Leu Ala Ile Pro Ala Pro Asp Gly Asn Met Thr Gly Phe Pro 20 25 30Phe Glu Gln Leu Met Arg Arg Gln Ser Thr Pro Ser Ser Thr Gly Arg 35 40 45His Asn Gly Tyr Tyr Tyr Ser Trp Trp Thr Asp Gly Ala Ser Pro Val 50 55 60Gln Tyr Gln Asn Gly Asn Gly Gly Ser Tyr Ser Val Gln Trp Gln Ser65 70 75 80Gly Gly Asn Phe Val Gly Gly Lys Gly Trp Met Pro Gly Gly Ser Lys 85 90 95Ser Ile Thr Tyr Ser Gly Thr Phe Asn Pro Val Asn Asn Gly Asn Ala 100 105 110Tyr Leu Cys Ile Tyr Gly Trp Thr Gln Asn Pro Leu Val Glu Tyr Tyr 115 120 125Ile Leu Glu Asn Tyr Gly Glu Tyr Asn Pro Gly Asn Ser Ala Gln Ser 130 135 140Arg Gly Thr Leu Gln Ala Ala Gly Gly Thr Tyr Thr Leu His Glu Ser145 150 155 160Thr Arg Val Asn Gln Pro Ser Ile Glu Gly Thr Arg Thr Phe Gln Gln 165 170 175Tyr Trp Ala Ile Arg Gln Gln Lys Arg Asn Ser Gly Thr Val Asn Thr 180 185 190Gly Glu Phe Phe Gln Ala Trp Glu Arg Ala Gly Met Arg Met Gly Asn 195 200 205His Asn Tyr Met Ile Val Ala Thr Glu Gly Tyr Arg Ser Ala Gly Asn 210 215 220Ser Asn Ile Asn Val Gln Thr Pro Ala225 23029219PRTC. gracile 29Met Val Ser Phe Lys Ala Leu Leu Leu Gly Ala Ala Gly Ala Leu Ala1 5 10 15Phe Pro Phe Asn Val Thr Gln Met Asn Glu Leu Val Ala Arg Ala Gly 20 25 30Thr Pro Ser Gly Thr Gly Thr Asn Asn Gly Tyr Phe Tyr Ser Phe Trp 35 40 45Thr Asp Gly Gly Gly Thr Val Asn Tyr Gln Asn Gly Ala Gly Gly Ser 50 55 60Tyr Ser Val Gln Trp Gln Asn Cys Gly Asn Phe Val Gly Gly Lys Gly65 70 75 80Trp Asn Pro Gly Ala Ala Arg Thr Ile Asn Phe Ser Gly Thr Phe Ser 85 90 95Pro Gln Gly Asn Gly Tyr Leu Ala Ile Tyr Gly Trp Thr Gln Asn Pro 100 105 110Leu Val Glu Tyr Tyr Ile Val Glu Ser Phe Gly Thr Tyr Asp Pro Ser 115 120 125Ser Gln Ala Ser Lys Phe Gly Thr Ile Gln Gln Asp Gly Ser Thr Tyr 130 135 140Thr Ile Ala Lys Thr Thr Arg Val Asn Gln Pro Ser Ile Glu Gly Thr145 150 155 160Ser Thr Phe Asp Gln Phe Trp Ser Val Arg Gln Asn His Arg Ser Ser 165 170 175Gly Ser Val Asn Val Ala Ala His Phe Asn Ala Trp Ala Gln Ala Gly 180 185 190Leu Lys Leu Gly Ser His Asn Tyr Gln Ile Val Ala Thr Glu Gly Tyr 195 200 205Gln Ser Ser Gly Ser Ser Ser Ile Thr Val Ser 210 21530223PRTT. reesei 30Met Val Ser Phe Thr Ser Leu Leu Ala Gly Val Ala Ala Ile Ser Gly1 5 10 15Val Leu Ala Ala Pro Ala Ala Glu Val Glu Pro Val Ala Val Glu Lys 20 25 30Arg Gln Thr Ile Gln Pro Gly Thr Gly Tyr Asn Asn Gly Tyr Phe His 35 40 45Ser Tyr Trp Asn Asp Gly His Gly Gly Val Thr Tyr Thr Asn Gly Pro 50 55 60Gly Gly Gln Phe Ser Val Asn Trp Ser Asn Ser Gly Asn Phe Val Gly65 70 75 80Gly Lys Gly Trp Gln Pro Gly Thr Lys Asn Lys Val Ile Asn Phe Ser 85 90 95Gly Ser Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Ser Val Tyr Gly Trp 100 105 110Ser Arg Asn Pro Leu Ile Glu Tyr Tyr Ile Val Gly Asn Phe Gly Thr 115 120 125Tyr Asn Pro Ser Thr Gly Ala Thr Lys Leu Gly Glu Val Thr Ser Asp 130 135 140Gly Ser Val Tyr Asp Ile Tyr Arg Thr Gln Arg Val Asn Gln Pro Ser145 150 155 160Ile Ile Gly Thr Ala Thr Phe Tyr Gln Tyr Trp Ser Val Arg Arg Asn 165 170 175His Arg Ser Ser Gly Ser Val Asn Thr Ala Asn His Phe Asn Ala Trp 180 185 190Ala Gln Gln Gly Leu Thr Leu Gly Thr Met Asp Tyr Gln Ile Val Ala 195 200 205Val Glu Gly Tyr Phe Ser Ser Gly Ser Ala Ser Ile Thr Val Ser 210 215 22031223PRTT. reesei 31Met Val Ser Phe Thr Ser Leu Leu Ala Gly Val Ala Ala Ile Ser Gly1 5 10 15Val Leu Ala Ala Pro Ala Ala Glu Val Glu Ser Val Ala Val Glu Lys 20 25 30Arg Gln Thr Ile Gln Pro Gly Thr Gly Tyr Asn Asn Gly Tyr Phe Tyr 35 40 45Ser Tyr Trp Asn Asp Gly His Gly Gly Val Thr Tyr Thr Asn Gly Pro 50 55 60Gly Gly Gln Phe Ser Val Asn Trp Ser Asn Ser Gly Asn Phe Val Gly65 70 75 80Gly Lys Gly Trp Gln Pro Gly Thr Lys Asn Lys Val Ile Asn Phe Ser 85 90 95Gly Ser Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Ser Val Tyr Gly Trp 100 105 110Ser Arg Asn Pro Leu Ile Glu Tyr Tyr Ile Val Glu Asn Phe Gly Thr 115 120 125Tyr Asn Pro Ser Thr Gly Ala Thr Lys Leu Gly Glu Val Thr Ser Asp 130 135 140Gly Ser Val Tyr Asp Ile Tyr Arg Thr Gln Arg Val Asn Gln Pro Ser145 150 155 160Ile Ile Gly Thr Ala Thr Phe Tyr Gln Tyr Trp Ser Val Arg Arg Asn 165 170 175His Arg Ser Ser Gly Ser Val Asn Thr Ala Asn His Phe Asn Ala Trp 180 185 190Ala Gln Gln Gly Leu Thr Leu Gly Thr Met Asp Tyr Gln Ile Val Ala 195 200 205Val Glu Gly Tyr Phe Ser Ser Gly Ser Ala Ser Ile Thr Val Ser 210 215 22032222PRTT. reesei 32Met Val Ser Phe Thr Ser Leu Leu Ala Ala Ser Pro Pro Ser Arg Ala1 5 10 15Ser Cys Arg Pro Ala Ala Glu Val Glu Ser Val Ala Val Glu Lys Arg 20 25 30Gln Thr Ile Gln Pro Gly Thr Gly Tyr Asn Asn Gly Tyr Phe Tyr Ser 35 40 45Tyr Trp Asn Asp Gly His Gly Gly Val Thr Tyr Thr Asn Gly Pro Gly 50 55 60Gly Gln Phe Ser Val Asn Trp Ser Asn Ser Gly Asn Phe Val Gly Gly65 70 75 80Lys Gly Trp Gln Pro Gly Thr Lys Asn Lys Val Ile Asn Phe Ser Gly 85 90 95Ser Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Ser Val Tyr Gly Trp Ser 100 105 110Arg Asn Pro Leu Ile Glu Tyr Tyr Ile Val Glu Asn Phe Gly Thr Tyr 115 120 125Asn Pro Ser Thr Gly Ala Thr Lys Leu Gly Glu Val Thr Ser Asp Gly 130 135 140Ser Val Tyr Asp Ile Tyr Arg Thr Gln Arg Val Asn Gln Pro Ser Ile145 150 155 160Ile Gly Thr Ala Thr Phe Tyr Gln Tyr Trp Ser Val Arg Arg Asn His 165 170 175Arg Ser Ser Gly Ser Val Asn Thr Ala Asn His Phe Asn Ala Trp Ala 180 185 190Gln Gln Gly Leu Thr Leu Gly Thr Met Asp Tyr Gln Ile Val Ala Val 195 200 205Glu Gly Tyr Phe Ser Ser Gly Ser Ala Ser Ile Thr Val Ser 210 215 22033190PRTT. harzianum 33Gln Thr Ile Gly Pro Gly Thr Gly Tyr Ser Asn Gly Tyr Tyr Tyr Ser1 5 10 15Tyr Trp Asn Asp Gly His Ala Gly Val Thr Tyr Thr Asn Gly Gly Gly 20 25 30Gly Ser Phe Thr Val Asn Trp Ser Asn Ser Gly Asn Phe Val Ala Gly 35 40 45Lys Gly Trp Gln Pro Gly Thr Lys Asn Lys Val Ile Asn Phe Ser Gly 50 55 60Ser Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Ser Ile Tyr Gly Trp Ser65 70 75 80Arg Asn Pro Leu Ile Glu Tyr Tyr Ile Val Glu Asn Phe Gly Thr Tyr 85 90 95Asn Pro Ser Thr Gly Ala Thr Lys Leu Gly Glu Val Thr Ser Asp Gly 100 105 110Ser Val Tyr Asp Ile Tyr Arg Thr Gln Arg Val Asn Gln Pro Ser Ile 115 120 125Ile Gly Thr Ala Thr Phe Tyr Gln Tyr Trp Ser Val Arg Arg Asn His 130 135 140Arg Ser Ser Gly Ser Val Asn Thr Ala Asn His Phe Asn Ala Trp Ala145 150 155 160Ser His Gly Leu Thr Leu Gly Thr Met Asp Tyr Gln Ile Val Ala Val 165 170 175Glu Gly Tyr Phe Ser Ser Gly Ser Ala Ser Ile Thr Val Ser 180 185 19034223PRTT. viride 34Met Val Ser Phe Thr Thr Leu Leu Ala Gly Phe Val Ala Val Thr Gly1 5 10 15Val Leu Ser Ala Pro Thr Glu Thr Val Glu Val Val Asp Val Glu Lys 20 25 30Arg Gln Thr Ile Gly Pro Gly Thr Gly Phe Asn Asn Gly Tyr Tyr Tyr 35 40 45Ser Tyr Trp Asn Asp Gly His Ser Gly Val Thr Tyr Thr Asn Gly Ala 50 55 60Gly Gly Ser Phe Ser Val Asn Trp Ala Asn Ser Gly Asn Phe Val Gly65 70 75 80Gly Lys Gly Trp Asn Pro Gly Ser Ser Ser Arg Val Ile Asn Phe Ser 85 90 95Gly Ser Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Ser Val Tyr Gly Trp 100 105 110Ser Lys Asn Pro Leu Ile Glu Tyr Tyr Ile Val Glu Asn Phe Gly Thr 115 120 125Tyr Asn Pro Ser Thr Gly Thr Thr Lys Leu Gly Glu Val Thr Ser Asp 130 135 140Gly Ser Val Tyr Asp Ile Tyr Arg Thr Gln Arg Val Asn Gln Pro Ser145 150 155 160Ile Ile Gly Thr Ala Thr Phe Tyr Gln Tyr Trp Ser Val Arg Arg Asn 165 170 175His Ala Pro Ala Ala Arg Ser Arg Leu Arg Thr Thr Ser Asn Ala Trp 180 185 190Arg Asn Leu Gly Leu

Thr Leu Gly Thr Leu Asp Tyr Gln Ile Ile Ala 195 200 205Val Glu Gly Tyr Phe Ser Ser Gly Asn Ala Asn Ile Asn Val Ser 210 215 22035241PRTC. gracile 35Met Val Asn Phe Ser Ser Leu Phe Leu Ala Ala Ser Ala Ala Val Val1 5 10 15Ala Val Ala Ala Pro Gly Glu Leu Pro Gly Met His Lys Arg Gln Thr 20 25 30Leu Thr Ser Ser Gln Thr Gly Thr Asn Asn Gly Tyr Tyr Tyr Ser Phe 35 40 45Trp Thr Asp Gly Gln Gly Asn Val Gln Tyr Thr Asn Glu Ala Gly Gly 50 55 60Gln Tyr Ser Val Thr Trp Ser Gly Asn Gly Asn Trp Val Gly Gly Lys65 70 75 80Gly Trp Asn Pro Gly Ser Ala Arg Thr Ile Asn Tyr Thr Ala Asn Tyr 85 90 95Asn Pro Asn Gly Asn Ser Tyr Leu Ala Val Tyr Gly Trp Thr Arg Asn 100 105 110Pro Leu Ile Glu Tyr Tyr Val Val Glu Asn Phe Gly Thr Tyr Asn Pro 115 120 125Ser Thr Gly Ala Thr Arg Leu Gly Ser Val Thr Thr Asp Gly Ser Cys 130 135 140Tyr Asp Ile Tyr Arg Thr Gln Arg Val Asn Gln Pro Ser Ile Glu Gly145 150 155 160Thr Ser Thr Phe Tyr Gln Phe Trp Ser Val Arg Gln Asn Lys Arg Ser 165 170 175Gly Gly Ser Val Asn Met Ala Ala His Phe Asn Ala Trp Ala Ala Ala 180 185 190Gly Leu Gln Leu Gly Thr His Asp Tyr Gln Ile Val Ala Thr Glu Gly 195 200 205Tyr Tyr Ser Ser Gly Ser Ala Thr Val Asn Val Gly Ala Ser Ser Asp 210 215 220Gly Ser Thr Gly Gly Gly Ser Thr Gly Gly Gly Ser Thr Asn Val Ser225 230 235 240Phe36225PRTA. niger 36Met Leu Thr Lys Asn Leu Leu Leu Cys Phe Ala Ala Ala Lys Ala Ala1 5 10 15Leu Ala Val Pro His Asp Ser Val Ala Gln Arg Ser Asp Ala Leu His 20 25 30Met Leu Ser Glu Arg Ser Thr Pro Ser Ser Thr Gly Glu Asn Asn Gly 35 40 45Phe Tyr Tyr Ser Phe Trp Thr Asp Gly Gly Gly Asp Val Thr Tyr Thr 50 55 60Asn Gly Asp Ala Gly Ala Tyr Thr Val Glu Trp Ser Asn Val Gly Asn65 70 75 80Phe Val Gly Gly Lys Gly Trp Asn Pro Gly Ser Ala Gln Asp Ile Thr 85 90 95Tyr Ser Gly Thr Phe Thr Pro Ser Gly Asn Gly Tyr Leu Ser Val Tyr 100 105 110Gly Trp Thr Thr Asp Pro Leu Ile Glu Tyr Tyr Ile Val Glu Ser Tyr 115 120 125Gly Asp Tyr Asn Pro Gly Ser Gly Gly Thr Tyr Lys Gly Thr Val Thr 130 135 140Ser Asp Gly Ser Val Tyr Asp Ile Tyr Thr Ala Thr Arg Thr Asn Ala145 150 155 160Ala Ser Ile Gln Gly Thr Ala Thr Phe Thr Gln Tyr Trp Ser Val Arg 165 170 175Gln Asn Lys Arg Val Gly Gly Thr Val Thr Thr Ser Asn His Phe Asn 180 185 190Ala Trp Ala Lys Leu Gly Met Asn Leu Gly Thr His Asn Tyr Gln Ile 195 200 205Val Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser Ser Ile Thr Val 210 215 220Gln22537221PRTPenicillium sp 40 37Met Lys Ser Phe Ile Ala Tyr Leu Leu Ala Ser Val Ala Val Thr Gly1 5 10 15Val Met Ala Val Pro Gly Glu Tyr His Lys Arg His Asp Lys Arg Gln 20 25 30Thr Ile Thr Ser Ser Gln Thr Gly Thr Asn Asn Gly Tyr Tyr Tyr Ser 35 40 45Phe Trp Thr Asn Gly Gly Gly Thr Val Gln Tyr Thr Asn Gly Ala Ala 50 55 60Gly Glu Tyr Ser Val Thr Trp Glu Asn Cys Gly Asp Phe Thr Ser Gly65 70 75 80Lys Gly Trp Ser Thr Gly Ser Ala Arg Asp Ile Thr Phe Glu Gly Thr 85 90 95Phe Asn Pro Ser Gly Asn Ala Tyr Leu Ala Val Tyr Gly Trp Thr Thr 100 105 110Ser Pro Leu Val Glu Tyr Tyr Ile Leu Glu Asp Tyr Gly Asp Tyr Asn 115 120 125Pro Gly Asn Ser Met Thr Tyr Lys Gly Thr Val Thr Ser Asp Gly Ser 130 135 140Val Tyr Asp Ile Tyr Glu His Gln Gln Val Asn Gln Pro Ser Ile Ser145 150 155 160Gly Thr Ala Thr Phe Asn Gln Tyr Trp Ser Ile Arg Gln Asn Thr Arg 165 170 175Ser Ser Gly Thr Val Thr Thr Ala Asn His Phe Asn Ala Trp Ala Lys 180 185 190Leu Gly Met Asn Leu Gly Ser Phe Asn Tyr Gln Ile Val Ser Thr Glu 195 200 205Gly Tyr Glu Ser Ser Gly Ser Ser Thr Ile Thr Val Ser 210 215 22038240PRTStreptomyces sp 38Met Gln Gln Asp Gly Lys Arg Gln Asp Gln Asn Gln Gln Asn Pro Ala1 5 10 15Pro Phe Ser Gly Leu Ser Arg Arg Gly Phe Leu Gly Gly Ala Gly Thr 20 25 30Val Ala Leu Ala Thr Ala Ser Gly Leu Leu Leu Pro Ser Thr Ala His 35 40 45Ala Ala Thr Thr Ile Thr Thr Asn Gln Thr Gly Tyr Asp Gly Met Tyr 50 55 60Tyr Ser Phe Trp Thr Asp Gly Gly Gly Ser Val Ser Met Thr Leu Asn65 70 75 80Gly Gly Gly Ser Tyr Ser Thr Gln Trp Thr Asn Cys Gly Asn Phe Val 85 90 95Ala Gly Lys Gly Trp Gly Asn Gly Gly Arg Arg Thr Val Arg Tyr Ser 100 105 110Gly Tyr Phe Asn Pro Ser Gly Asn Gly Tyr Gly Cys Leu Tyr Gly Trp 115 120 125Thr Ser Asn Pro Leu Val Glu Tyr Tyr Ile Val Asp Asn Trp Gly Ser 130 135 140Tyr Arg Pro Thr Gly Glu Tyr Arg Gly Thr Val Tyr Ser Asp Gly Gly145 150 155 160Thr Tyr Asp Ile Tyr Lys Thr Thr Arg Tyr Asn Ala Pro Ser Val Glu 165 170 175Gly Thr Arg Thr Phe Asp Gln Tyr Trp Ser Val Arg Gln Ser Lys Val 180 185 190Ile Gly Ser Gly Thr Ile Thr Thr Gly Asn His Phe Asp Ala Trp Ala 195 200 205Arg Ala Gly Met Asn Leu Gly Gln Phe Gln Tyr Tyr Met Ile Met Ala 210 215 220Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser Asn Ile Thr Val Ser Gly225 230 235 24039228PRTStreptomyces sp 39Met Thr Lys Asp Asn Thr Pro Ile Arg Pro Val Ser Arg Arg Gly Phe1 5 10 15Ile Gly Arg Ala Gly Ala Leu Ala Leu Ala Thr Ser Gly Leu Met Leu 20 25 30Pro Gly Thr Ala Arg Ala Asp Thr Val Ile Thr Thr Asn Gln Thr Gly 35 40 45Thr Asn Asn Gly Tyr Tyr Tyr Ser Phe Trp Thr Asp Gly Gly Gly Ser 50 55 60Val Ser Met Asn Leu Ala Ser Gly Gly Ser Tyr Gly Thr Ser Trp Thr65 70 75 80Asn Cys Gly Asn Phe Val Ala Gly Lys Gly Trp Ala Asn Gly Ala Arg 85 90 95Arg Thr Val Asn Tyr Ser Gly Ser Phe Asn Pro Ser Gly Asn Ala Tyr 100 105 110Leu Thr Leu Tyr Gly Trp Thr Ala Asn Pro Leu Val Glu Tyr Tyr Ile 115 120 125Val Asp Asn Trp Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Thr 130 135 140Val Thr Ser Asp Gly Gly Thr Tyr Asp Val Tyr Gln Thr Thr Arg Val145 150 155 160Asn Ala Pro Ser Val Glu Gly Thr Lys Thr Phe Asn Gln Tyr Trp Ser 165 170 175Val Arg Gln Ser Lys Arg Thr Gly Gly Ser Ile Thr Ala Gly Asn His 180 185 190Phe Asp Ala Trp Ala Arg Tyr Gly Met Pro Leu Gly Ser Phe Asn Tyr 195 200 205Tyr Met Ile Met Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser Ser 210 215 220Ile Ser Val Ser22540239PRTS. thermocyaneoviolaceus 40Met Asn Thr Leu Val His Pro Gln Gly Arg Ala Gly Gly Leu Arg Leu1 5 10 15Leu Val Arg Ala Ala Trp Ala Leu Ala Leu Ala Ala Leu Ala Ala Met 20 25 30Met Phe Gly Gly Thr Ala Arg Ala Asp Thr Ile Thr Ser Asn Gln Thr 35 40 45Gly Thr His Asn Gly Tyr Phe Tyr Ser Phe Trp Thr Asp Ala Pro Gly 50 55 60Thr Val Thr Met Asn Thr Gly Ala Gly Gly Asn Tyr Ser Thr Gln Trp65 70 75 80Ser Asn Thr Gly Asn Phe Val Ala Gly Lys Gly Trp Ala Thr Gly Gly 85 90 95Arg Arg Thr Val Thr Tyr Ser Gly Thr Phe Asn Pro Ser Gly Asn Ala 100 105 110Tyr Leu Ala Leu Tyr Gly Trp Ser Gln Asn Pro Leu Val Glu Tyr Tyr 115 120 125Ile Val Asp Asn Trp Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly 130 135 140Thr Val Tyr Ser Asp Gly Gly Thr Tyr Asp Ile Tyr Met Thr Thr Arg145 150 155 160Tyr Asn Ala Pro Ser Ile Glu Gly Thr Lys Thr Phe Asn Gln Tyr Trp 165 170 175Ser Val Arg Gln Asn Lys Arg Thr Gly Gly Thr Ile Thr Thr Gly Asn 180 185 190His Phe Asp Ala Trp Ala Ala His Gly Met Pro Leu Gly Thr Phe Asn 195 200 205Tyr Met Ile Leu Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser Asn 210 215 220Ile Thr Val Gly Asp Ser Gly Gly Asp Asn Gly Gly Gly Gly Gly225 230 23541242PRTS. viridosporus 41Met Asn Ala Phe Ala His Pro Arg Gly Arg Arg His Gly Arg Ser Ala1 5 10 15Pro Met Ser Pro Arg Ser Thr Trp Ala Val Leu Leu Ala Ala Leu Ala 20 25 30Val Met Leu Leu Pro Gly Thr Ala Thr Ala Ala Pro Val Ile Thr Thr 35 40 45Asn Gln Thr Gly Thr Asn Asn Gly Trp Trp Tyr Ser Phe Trp Thr Asp 50 55 60Ala Gln Gly Thr Val Ser Met Asp Leu Gly Ser Gly Gly Thr Tyr Ser65 70 75 80Thr Gln Trp Arg Asn Thr Gly Asn Phe Val Ala Gly Lys Gly Trp Ser 85 90 95Thr Gly Gly Arg Lys Thr Val Asn Tyr Ser Gly Thr Phe Asn Pro Ser 100 105 110Gly Asn Ala Tyr Leu Thr Leu Tyr Gly Trp Thr Thr Gly Pro Leu Ile 115 120 125Glu Tyr Tyr Ile Val Asp Asn Trp Gly Thr Tyr Arg Pro Thr Gly Lys 130 135 140Tyr Lys Gly Thr Val Thr Ser Asp Gly Gly Thr Tyr Asp Ile Tyr Lys145 150 155 160Thr Thr Arg Tyr Asn Ala Pro Ser Ile Glu Gly Thr Lys Thr Phe Asp 165 170 175Gln Tyr Trp Ser Val Arg Gln Ser Lys Arg Thr Gly Gly Thr Ile Thr 180 185 190Ser Gly Asn His Phe Asp Ala Trp Ala Arg Asn Gly Met Asn Leu Gly 195 200 205Asn His Asn Tyr Met Ile Met Ala Thr Glu Gly Tyr Gln Ser Ser Gly 210 215 220Ser Ser Thr Ile Thr Val Ser Glu Ser Gly Ser Gly Gly Gly Gly Gly225 230 235 240Gly Gly42240PRTT. fusca 42Met Asn His Ala Pro Ala Ser Leu Lys Ser Arg Arg Arg Phe Arg Pro1 5 10 15Arg Leu Leu Ile Gly Lys Ala Phe Ala Ala Ala Leu Val Ala Val Val 20 25 30Thr Met Ile Pro Ser Thr Ala Ala His Ala Ala Val Thr Ser Asn Glu 35 40 45Thr Gly Tyr His Asp Gly Tyr Phe Tyr Ser Phe Trp Thr Asp Ala Pro 50 55 60Gly Thr Val Ser Met Glu Leu Gly Pro Gly Gly Asn Tyr Ser Thr Ser65 70 75 80Trp Arg Asn Thr Gly Asn Phe Val Ala Gly Lys Gly Trp Ala Thr Gly 85 90 95Gly Arg Arg Thr Val Thr Tyr Ser Ala Ser Phe Asn Pro Ser Gly Asn 100 105 110Ala Tyr Leu Thr Leu Tyr Gly Trp Thr Arg Asn Pro Leu Val Glu Tyr 115 120 125Tyr Ile Val Glu Ser Trp Gly Thr Tyr Arg Pro Thr Gly Thr Tyr Met 130 135 140Gly Thr Val Thr Thr Asp Gly Gly Thr Tyr Asp Ile Tyr Lys Thr Thr145 150 155 160Arg Tyr Asn Ala Pro Ser Ile Glu Gly Thr Arg Thr Phe Asp Gln Tyr 165 170 175Trp Ser Val Arg Gln Ser Lys Arg Thr Ser Gly Thr Ile Thr Ala Gly 180 185 190Asn His Phe Asp Ala Trp Ala Arg His Gly Met His Leu Gly Thr His 195 200 205Asp Tyr Met Ile Met Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser Ser 210 215 220Asn Val Thr Leu Gly Thr Ser Gly Gly Gly Asn Pro Gly Gly Gly Asn225 230 235 24043241PRTC. pachnodae 43Met Thr Arg Thr Ile Ser Arg Ala Ala His Arg Pro Pro Ala Gly Gly1 5 10 15Arg Ile Ala Arg Ala Leu Ala Ala Ala Gly Ala Thr Val Ala Met Val 20 25 30Ile Ala Gly Val Ala Ala Ala Gln Pro Ala Ala Ala Val Asp Ser Asn 35 40 45Ser Thr Gly Ser Ser Gly Gly Tyr Phe Tyr Ser Phe Trp Thr Asp Ala 50 55 60Pro Gly Thr Val Ser Met Asn Leu Gly Ser Gly Gly Asn Tyr Ser Thr65 70 75 80Ser Trp Ser Asn Thr Gly Asn Phe Val Ala Gly Lys Gly Trp Ser Thr 85 90 95Gly Ser Ala Arg Thr Ile Ser Tyr Ser Gly Thr Phe Asn Pro Ser Gly 100 105 110Asn Ala Tyr Leu Ala Val Tyr Gly Trp Ser His Asp Pro Leu Val Glu 115 120 125Tyr Tyr Ile Val Asp Ser Trp Gly Thr Tyr Arg Pro Thr Gly Thr Phe 130 135 140Met Gly Thr Val Asn Ser Asp Gly Gly Thr Tyr Asp Ile Tyr Lys Thr145 150 155 160Thr Arg Thr Asn Ala Pro Ser Ile Glu Gly Thr Ala Thr Phe Thr Gln 165 170 175Tyr Trp Ser Val Arg Gln Ser Lys Arg Val Gly Gly Thr Ile Thr Thr 180 185 190Ala Asn His Phe Asn Ala Trp Ala Ser His Gly Met Asn Leu Gly Arg 195 200 205His Asp Tyr Gln Ile Leu Ala Thr Glu Gly Tyr Gln Ser Ser Gly Ser 210 215 220Ser Asn Ile Thr Ile Gly Ser Thr Ser Gly Gly Gly Gly Ser Gly Gly225 230 235 240Gly44221PRTA. oryzae 44Met Val Ser Phe Ser Ser Leu Leu Leu Ala Val Ser Ala Val Ser Gly1 5 10 15Ala Leu Ala Ala Pro Gly Asp Ser Thr Leu Val Glu Leu Ala Lys Arg 20 25 30Ala Ile Thr Ser Ser Glu Thr Gly Thr Asn Asn Gly Tyr Tyr Tyr Ser 35 40 45Phe Trp Thr Asn Gly Gly Gly Asp Val Glu Tyr Thr Asn Gly Asn Gly 50 55 60Gly Gln Tyr Ser Val Lys Trp Thr Asn Cys Asp Asn Phe Val Ala Gly65 70 75 80Lys Gly Trp Asn Pro Gly Ser Ala Lys Thr Val Thr Tyr Ser Gly Glu 85 90 95Trp Glu Ser Asn Ser Asn Ser Tyr Val Ser Leu Tyr Gly Trp Thr Gln 100 105 110Asn Pro Leu Val Glu Tyr Tyr Ile Val Asp Lys Tyr Gly Asp Tyr Asp 115 120 125Pro Ser Thr Gly Ala Thr Glu Leu Gly Thr Val Glu Ser Asp Gly Gly 130 135 140Thr Tyr Lys Ile Tyr Lys Thr Thr Arg Glu Asn Ala Pro Ser Ile Glu145 150 155 160Gly Thr Ser Thr Phe Asn Gln Tyr Trp Ser Val Arg Gln Ser Gly Arg 165 170 175Val Gly Gly Thr Ile Thr Ala Gln Asn His Phe Asp Ala Trp Ala Asn 180 185 190Val Gly Leu Gln Leu Gly Thr His Asn Tyr Met Ile Leu Ala Thr Glu 195 200 205Gly Tyr Lys Ser Ser Gly Ser Ala Thr Ile Thr Val Glu 210 215 22045216PRTC. purpurea 45Met Phe Leu Thr Ser Val Val Ser Leu Val Val Gly Ala Ile Ser Cys1 5 10 15Val Ser Ala Ala Pro Ala Ala Ala Ser Glu Leu Met Gln Met Thr Pro 20 25 30Arg Asn Ser Cys Tyr Gly Gly Gly Leu Tyr Ser Ser Tyr Trp Ala Asp 35 40 45Tyr Gly Asn Thr Arg Tyr Ser Cys Gly Ala Gly Gly His Tyr Asp Leu 50 55 60Ser Trp Gly Asn Gly Gly Asn Val Val Ala Gly Arg Gly Trp Lys Pro65 70 75 80Ala Ser Pro Arg Ala Val Thr Tyr Ser Gly Ser Trp Gln Cys

Asn Gly 85 90 95Asn Cys Tyr Leu Ser Val Tyr Gly Trp Thr Ile Asn Pro Leu Val Glu 100 105 110Tyr Tyr Ile Val Glu Asn Tyr Gly Asn Tyr Asn Pro Ser Ala Gly Ala 115 120 125Gln Arg Arg Gly Gln Val Thr Ala Asp Gly Ser Ile Tyr Asp Ile Tyr 130 135 140Ile Ser Thr Gln His Asn Gln Pro Ser Ile Leu Gly Thr Asn Thr Phe145 150 155 160His Gln Tyr Trp Ser Ile Arg Arg Asn Lys Arg Val Gly Gly Thr Val 165 170 175Ser Thr Gly Val His Phe Asn Ala Trp Arg Ser Leu Gly Met Pro Leu 180 185 190Gly Thr Tyr Asp Tyr Met Ile Val Ala Thr Glu Gly Phe Arg Ser Ser 195 200 205Gly Ser Ala Ser Ile Thr Val Ser 210 21546236PRTC. mixtus 46Met Lys Phe Pro Leu Ile Gly Lys Ser Thr Leu Ala Ala Leu Phe Cys1 5 10 15Ser Ala Leu Leu Gly Val Asn Asn Thr Gln Ala Gln Thr Leu Thr Asn 20 25 30Asn Ala Thr Gly Thr His Asn Gly Phe Tyr Tyr Thr Phe Trp Lys Asp 35 40 45Ser Gly Asp Ala Ser Met Gly Leu Gln Ala Gly Gly Arg Tyr Thr Ser 50 55 60Gln Trp Ser Asn Gly Thr Asn Asn Trp Val Gly Gly Lys Gly Trp Asn65 70 75 80Pro Gly Gly Pro Lys Val Val Thr Tyr Ser Gly Ser Tyr Asn Val Asp 85 90 95Asn Ser Gln Asn Ser Tyr Leu Ala Leu Tyr Gly Trp Thr Arg Ser Pro 100 105 110Leu Ile Glu Tyr Tyr Val Ile Glu Ser Tyr Gly Ser Tyr Asn Pro Ala 115 120 125Ser Cys Ser Gly Gly Thr Asp Tyr Gly Ser Phe Gln Ser Asp Gly Ala 130 135 140Thr Tyr Asn Val Arg Arg Cys Gln Arg Val Gln Gln Pro Ser Ile Asp145 150 155 160Gly Thr Gln Thr Phe Tyr Gln Tyr Phe Ser Val Arg Ser Pro Lys Lys 165 170 175Gly Phe Gly Gln Ile Ser Gly Thr Ile Thr Thr Ala Asn His Phe Asn 180 185 190Phe Trp Ala Ser Lys Gly Leu Asn Leu Gly Asn His Asp Tyr Met Val 195 200 205Leu Ala Thr Glu Gly Tyr Gln Ser Arg Gly Ser Ser Asp Ile Thr Val 210 215 220Ser Glu Gly Thr Gly Gly Thr Thr Ser Ser Ser Val225 230 23547237PRTP. fluorescens cellulosa 47Met Lys Leu Pro Thr Leu Gly Lys Cys Val Val Arg Thr Leu Met Gly1 5 10 15Ala Val Ala Leu Gly Ala Ile Ser Val Asn Ala Gln Thr Leu Ser Ser 20 25 30Asn Ser Thr Gly Thr Asn Asn Gly Phe Tyr Tyr Thr Phe Trp Lys Asp 35 40 45Ser Gly Asp Ala Ser Met Thr Leu Leu Ser Gly Gly Arg Tyr Gln Ser 50 55 60Ser Trp Gly Asn Ser Thr Asn Asn Trp Val Gly Gly Lys Gly Trp Asn65 70 75 80Pro Gly Asn Asn Ser Arg Val Ile Ser Tyr Ser Gly Ser Tyr Gly Val 85 90 95Asp Ser Ser Gln Asn Ser Tyr Leu Ala Leu Tyr Gly Trp Thr Arg Ser 100 105 110Pro Leu Ile Glu Tyr Tyr Val Ile Glu Ser Tyr Gly Ser Tyr Asn Pro 115 120 125Ala Ser Cys Ser Gly Gly Thr Asp Tyr Gly Ser Phe Gln Ser Asp Gly 130 135 140Ala Thr Tyr Asn Val Arg Arg Cys Gln Arg Val Asn Gln Pro Ser Ile145 150 155 160Asp Gly Thr Gln Thr Phe Tyr Gln Tyr Phe Ser Val Arg Asn Pro Lys 165 170 175Lys Gly Phe Gly Asn Ile Ser Gly Thr Ile Thr Phe Ala Asn His Val 180 185 190Asn Phe Trp Ala Ser Lys Gly Leu Asn Leu Gly Asn His Asn Tyr Gln 195 200 205Val Leu Ala Thr Glu Gly Tyr Gln Ser Arg Gly Ser Ser Asp Ile Thr 210 215 220Val Ser Glu Gly Thr Ser Gly Gly Gly Thr Ser Ser Val225 230 23548217PRTP. cochleariae 48Met Gln Phe Leu Ile Pro Val Val Ile Leu Cys Val Ser Leu Val Asp1 5 10 15Ser Gln Lys Val Leu Tyr Asn Asn Glu Ile Gly Phe Asn Asn Gly Phe 20 25 30Tyr Tyr Ala Phe Trp Lys Asp Ser Gly Ser Ala Thr Phe Thr Leu Glu 35 40 45Ser Gly Gly Arg Tyr Ala Gly Asn Trp Thr Thr Ser Thr Asn Asn Trp 50 55 60Val Gly Gly Lys Gly Trp Asn Pro Gly Asn Ser Trp Arg Thr Val Asn65 70 75 80Tyr Ser Gly Tyr Tyr Gly Ile Asn Glu Tyr Ala Asn Ser Tyr Leu Ser 85 90 95Leu Tyr Gly Trp Thr Thr Asn Pro Leu Ile Glu Tyr Tyr Val Val Glu 100 105 110Ser Tyr Gly Ser Tyr Ser Pro Leu Asn Cys Pro Gly Gly Thr Asp Glu 115 120 125Gly Ser Phe Thr Ser Gly Gly Ala Thr Tyr Gln Val Arg Lys Cys Arg 130 135 140Arg Thr Asn Ala Pro Ser Ile Ile Gly Thr Gln Ser Phe Asp Gln Tyr145 150 155 160Phe Ser Val Arg Thr Pro Lys Lys Gly Phe Gly Gln Val Ser Gly Ser 165 170 175Val Asn Phe Ala Asp His Val Gln Tyr Trp Ala Ser Lys Gly Leu Pro 180 185 190Leu Gly Thr His Ala His Gln Ile Phe Ala Thr Glu Gly Tyr Gln Ser 195 200 205Ser Gly Phe Ala Asp Ile Thr Val Ser 210 21549182PRTA. kawachi 49Ala Gly Ile Asn Tyr Val Gln Asn Tyr Asn Gly Asn Leu Gly Asp Phe1 5 10 15Thr Tyr Asp Glu Ser Ala Gly Thr Phe Ser Met Tyr Trp Glu Asp Gly 20 25 30Val Ser Ser Asp Phe Val Val Gly Leu Gly Trp Thr Thr Gly Ser Ser 35 40 45Asn Ala Ile Thr Tyr Ser Ala Glu Tyr Ser Ala Ser Gly Ser Ser Ser 50 55 60Tyr Leu Ala Val Tyr Gly Trp Val Asn Tyr Pro Gln Ala Glu Tyr Tyr65 70 75 80Ile Val Glu Asp Tyr Gly Asp Tyr Asn Pro Cys Ser Ser Ala Thr Ser 85 90 95Leu Gly Thr Val Tyr Ser Asp Gly Ser Thr Tyr Gln Val Cys Thr Asp 100 105 110Thr Arg Thr Asn Glu Pro Ser Ile Thr Gly Thr Ser Thr Phe Thr Gln 115 120 125Tyr Phe Ser Val Arg Glu Ser Thr Arg Thr Ser Gly Thr Val Thr Val 130 135 140Ala Asn His Phe Asn Phe Trp Ala Gln His Gly Phe Gly Asn Ser Asp145 150 155 160Phe Asn Tyr Gln Val Met Ala Val Glu Ala Trp Ser Gly Ala Gly Ser 165 170 175Ala Ser Val Thr Ile Ser 18050211PRTA. niger 50Met Lys Val Thr Ala Ala Phe Ala Gly Leu Leu Val Thr Ala Phe Ala1 5 10 15Ala Pro Val Pro Glu Pro Val Leu Val Ser Arg Ser Ala Gly Ile Asn 20 25 30Tyr Val Gln Asn Tyr Asn Gly Asn Leu Gly Asp Phe Thr Tyr Asp Glu 35 40 45Ser Ala Gly Thr Phe Ser Met Tyr Trp Glu Asp Gly Val Ser Ser Asp 50 55 60Phe Val Val Gly Leu Gly Trp Thr Thr Gly Ser Ser Lys Ala Ile Thr65 70 75 80Tyr Ser Ala Glu Tyr Ser Ala Ser Gly Ser Ser Ser Tyr Leu Ala Val 85 90 95Tyr Gly Trp Val Asn Tyr Pro Gln Ala Glu Tyr Tyr Ile Val Glu Asp 100 105 110Tyr Gly Asp Tyr Asn Pro Cys Ser Ser Ala Thr Ser Leu Gly Thr Val 115 120 125Tyr Ser Asp Gly Ser Thr Tyr Gln Val Cys Thr Asp Thr Arg Thr Asn 130 135 140Glu Pro Ser Ile Thr Gly Thr Ser Thr Phe Thr Gln Tyr Phe Ser Val145 150 155 160Arg Glu Ser Thr Arg Thr Ser Gly Thr Val Thr Val Ala Asn His Phe 165 170 175Asn Phe Trp Ala Gln His Gly Phe Gly Asn Ser Asp Phe Asn Tyr Gln 180 185 190Val Met Ala Val Glu Ala Trp Ser Gly Ala Gly Ser Ala Ser Val Thr 195 200 205Ile Ser Ser 21051210PRTA .tubigensis 51Met Lys Val Thr Ala Ala Phe Ala Gly Leu Leu Val Thr Ala Phe Ala1 5 10 15Ala Pro Ala Pro Glu Pro Asp Leu Val Ser Arg Ser Ala Gly Ile Asn 20 25 30Tyr Val Gln Asn Tyr Asn Gly Asn Leu Gly Asp Phe Thr Tyr Asp Glu 35 40 45Ser Ala Gly Thr Phe Ser Met Tyr Trp Glu Asp Gly Val Ser Ser Asp 50 55 60Phe Val Val Gly Leu Gly Trp Thr Thr Gly Ser Ser Thr Ile Thr Tyr65 70 75 80Ser Ala Glu Tyr Ser Ala Ser Gly Ser Ala Ser Tyr Leu Ala Val Tyr 85 90 95Gly Trp Val Asn Tyr Pro Gln Ala Glu Tyr Tyr Ile Val Glu Asp Tyr 100 105 110Gly Asp Tyr Asn Pro Cys Ser Ser Ala Thr Ser Leu Gly Thr Val Tyr 115 120 125Ser Asp Gly Ser Thr Tyr Gln Val Cys Thr Asp Thr Arg Thr Asn Glu 130 135 140Pro Ser Ile Thr Gly Thr Ser Thr Phe Thr Gln Tyr Phe Ser Val Arg145 150 155 160Glu Ser Thr Arg Thr Ser Gly Thr Val Thr Val Ala Asn His Phe Asn 165 170 175Phe Trp Ala His His Gly Phe Gly Asn Ser Asp Phe Asn Tyr Gln Val 180 185 190Val Ala Val Glu Ala Trp Ser Gly Ala Gly Ser Ala Ser Val Thr Ile 195 200 205Ser Ser 21052208PRTP. purpurogenum 52Met Lys Val Thr Ala Ala Phe Ala Gly Leu Leu Ala Arg His Ser Pro1 5 10 15Pro Leu Ser Thr Glu Leu Val Thr Arg Ser Ile Asn Tyr Val Gln Asn 20 25 30Tyr Asn Gly Asn Leu Gly Ala Phe Ser Tyr Asn Glu Gly Ala Gly Thr 35 40 45Phe Ser Met Tyr Trp Gln Gln Gly Val Ser Asn Asp Phe Val Val Gly 50 55 60Leu Gly Arg Ser Thr Gly Ser Ser Asn Pro Ile Thr Tyr Ser Ala Ser65 70 75 80Tyr Ser Ala Ser Gly Gly Ser Tyr Leu Ala Val Tyr Gly Trp Val Asn 85 90 95Ser Pro Gln Ala Glu Tyr Tyr Val Val Glu Ala Tyr Gly Asn Tyr Asn 100 105 110Pro Cys Ser Ser Gly Ser Ala Thr Asn Leu Gly Thr Val Ser Ser Asp 115 120 125Gly Gly Thr Tyr Gln Val Cys Thr Asp Thr Arg Val Asn Gln Pro Ser 130 135 140Ile Thr Gly Thr Ser Thr Phe Thr Gln Phe Phe Ser Val Arg Gln Gly145 150 155 160Ser Arg Thr Ser Gly Thr Val Thr Ile Ala Asn His Phe Asn Phe Trp 165 170 175Ala Asn Asp Gly Phe Gly Asn Ser Asn Phe Asn Tyr Gln Val Val Ala 180 185 190Val Glu Ala Trp Ser Gly Thr Gly Thr Ala Ser Val Thr Val Ser Ala 195 200 20553233PRTP. purpurogenum 53Met Lys Val Thr Ala Ala Phe Ala Gly Leu Leu Ala Arg His Ser Pro1 5 10 15Pro Leu Ser Thr Glu Leu Val Thr Arg Ser Ile Asn Tyr Val Gln Asn 20 25 30Tyr Asn Gly Asn Leu Gly Ala Phe Ser Tyr Asn Glu Gly Ala Gly Thr 35 40 45Phe Ser Met Tyr Trp Gln Gln Gly Val Ser Asn Asp Phe Val Val Gly 50 55 60Leu Gly Arg Ser Thr Gly Ser Ser Asn Pro Ile Thr Tyr Ser Ala Ser65 70 75 80Tyr Ser Ala Ser Gly Gly Ser Tyr Leu Ala Val Tyr Gly Trp Val Asn 85 90 95Ser Pro Gln Ala Glu Tyr Tyr Val Val Glu Ala Tyr Gly Asn Tyr Asn 100 105 110Pro Cys Ser Ser Gly Ser Ala Thr Asn Leu Gly Thr Val Ser Ser Asp 115 120 125Gly Gly Thr Tyr Gln Val Cys Thr Asp Thr Arg Val Asn Gln Pro Ser 130 135 140Ile Thr Gly Thr Ser Thr Phe Thr Gln Phe Phe Ser Val Arg Gln Gly145 150 155 160Ser Arg Thr Ser Gly Thr Val Thr Ile Ala Asn His Phe Asn Phe Trp 165 170 175Ala Asn Asp Gly Phe Gly Asn Ser Asn Phe Asn Tyr Gln Val Val Ala 180 185 190Val Glu Ala Trp Ser Gly Thr Gly Thr Ala Ser Val Thr Val Ser Ala 195 200 205Asn Phe Asn Tyr Gln Val Leu Ala Val Glu Gly Phe Ser Gly Ser Gly 210 215 220Asn Ala Asn Met Lys Leu Ile Ser Gly225 23054229PRTT. reesei 54Met Val Ala Phe Ser Ser Leu Ile Cys Ala Leu Thr Ser Ile Ala Ser1 5 10 15Thr Leu Ala Met Pro Thr Gly Leu Glu Pro Glu Ser Ser Val Asn Val 20 25 30Thr Glu Arg Gly Met Tyr Asp Phe Val Leu Gly Ala His Asn Asp His 35 40 45Arg Arg Arg Ala Ser Ile Asn Tyr Asp Gln Asn Tyr Gln Thr Gly Gly 50 55 60Gln Val Ser Tyr Ser Pro Ser Asn Thr Gly Phe Ser Val Asn Trp Asn65 70 75 80Thr Gln Asp Asp Phe Val Val Gly Val Gly Trp Thr Thr Gly Ser Ser 85 90 95Ala Pro Ile Asn Phe Gly Gly Ser Phe Ser Val Asn Ser Gly Thr Gly 100 105 110Leu Leu Ser Val Tyr Gly Trp Ser Thr Asn Pro Leu Val Glu Tyr Tyr 115 120 125Ile Met Glu Asp Asn His Asn Tyr Pro Ala Gln Gly Thr Val Lys Gly 130 135 140Thr Val Thr Ser Asp Gly Ala Thr Tyr Thr Ile Trp Glu Asn Thr Arg145 150 155 160Val Asn Glu Pro Ser Ile Gln Gly Thr Ala Thr Phe Asn Gln Tyr Ile 165 170 175Ser Val Arg Asn Ser Pro Arg Thr Ser Gly Thr Val Thr Val Gln Asn 180 185 190His Phe Asn Ala Trp Ala Ser Leu Gly Leu His Leu Gly Gln Met Asn 195 200 205Tyr Gln Val Val Ala Val Glu Gly Trp Gly Gly Ser Gly Ser Ala Ser 210 215 220Gln Ser Val Ser Asn22555227PRTB. pumilus 55Met Asn Leu Lys Arg Leu Arg Leu Leu Phe Val Met Cys Ile Gly Phe1 5 10 15Val Leu Thr Leu Thr Ala Val Pro Ala His Ala Glu Thr Ile Tyr Asp 20 25 30Asn Arg Ile Gly Thr His Ser Gly Tyr Asp Phe Glu Leu Trp Lys Asp 35 40 45Tyr Gly Asn Thr Ser Met Thr Leu Asn Asn Gly Gly Ala Phe Ser Ala 50 55 60Ser Trp Asn Asn Ile Gly Asn Ala Leu Phe Arg Lys Gly Lys Lys Phe65 70 75 80Asp Ser Thr Lys Thr His His Gln Leu Gly Asn Ile Ser Ile Asn Tyr 85 90 95Asn Ala Ala Phe Asn Pro Gly Gly Asn Ser Tyr Leu Cys Val Tyr Gly 100 105 110Trp Thr Gln Ser Pro Leu Ala Glu Tyr Tyr Ile Val Glu Ser Trp Gly 115 120 125Thr Tyr Arg Pro Thr Gly Thr Tyr Lys Gly Ser Phe Tyr Ala Asp Gly 130 135 140Gly Thr Tyr Asp Ile Tyr Glu Thr Leu Arg Val Asn Gln Pro Ser Ile145 150 155 160Ile Gly Asp Ala Thr Phe Lys Gln Tyr Trp Ser Val Arg Gln Thr Lys 165 170 175Arg Thr Ser Gly Thr Ala Ser Val Ser Glu His Phe Lys Lys Trp Glu 180 185 190Ser Leu Gly Met Pro Met Gly Lys Met Tyr Glu Thr Ala Leu Thr Val 195 200 205Glu Gly Tyr Arg Ser Asn Gly Ser Ala Asn Val Met Thr Asn Gln Leu 210 215 220Met Ile Arg22556228PRTB. pumilus 56Met Asn Leu Arg Lys Leu Arg Leu Leu Phe Val Met Cys Ile Gly Leu1 5 10 15Thr Leu Ile Leu Thr Ala Val Pro Ala His Ala Arg Thr Ile Thr Asn 20 25 30Asn Glu Met Gly Asn His Ser Gly Tyr Asp Tyr Glu Leu Trp Lys Asp 35 40 45Tyr Gly Asn Thr Ser Met Thr Leu Asn Asn Gly Gly Ala Phe Ser Ala 50 55 60Gly Trp Asn Asn Ile Gly Asn Ala Leu Phe Arg Lys Gly Lys Lys Phe65 70 75 80Asp Ser Thr Arg Thr His His Gln Leu Gly Asn Ile Ser Ile Asn Tyr 85 90 95Asn Ala Ser Phe Asn Pro Gly Gly Asn Ser Tyr Leu Cys Val Tyr Gly 100 105 110Trp Thr Gln Ser Pro Leu Ala Glu Tyr Tyr Ile Val Asp Ser Trp Gly 115 120 125Thr Tyr Arg Pro Thr Gly Ala Tyr Lys Gly Ser Phe Tyr Ala Asp Gly 130

135 140Gly Thr Tyr Asp Ile Tyr Glu Thr Thr Arg Val Asn Gln Pro Ser Ile145 150 155 160Ile Gly Ile Ala Thr Phe Lys Gln Tyr Trp Ser Val Arg Gln Thr Lys 165 170 175Arg Thr Ser Gly Thr Val Ser Val Ser Ala His Phe Arg Lys Trp Glu 180 185 190Ser Leu Gly Met Pro Met Gly Lys Met Tyr Glu Thr Ala Phe Thr Val 195 200 205Glu Gly Tyr Gln Ser Ser Gly Ser Ala Asn Val Met Thr Asn Gln Leu 210 215 220Phe Ile Gly Asn22557261PRTC. acetobutylicum 57Met Leu Arg Arg Lys Val Ile Phe Thr Val Leu Ala Thr Leu Val Met1 5 10 15Thr Ser Leu Thr Ile Val Asp Asn Thr Ala Phe Ala Ala Thr Asn Leu 20 25 30Asn Thr Thr Glu Ser Thr Phe Ser Lys Glu Val Leu Ser Thr Gln Lys 35 40 45Thr Tyr Ser Ala Phe Asn Thr Gln Ala Ala Pro Lys Thr Ile Thr Ser 50 55 60Asn Glu Ile Gly Val Asn Gly Gly Tyr Asp Tyr Glu Leu Trp Lys Asp65 70 75 80Tyr Gly Asn Thr Ser Met Thr Leu Lys Asn Gly Gly Ala Phe Ser Cys 85 90 95Gln Trp Ser Asn Ile Gly Asn Ala Leu Phe Arg Lys Gly Lys Lys Phe 100 105 110Asn Asp Thr Gln Thr Tyr Lys Gln Leu Gly Asn Ile Ser Val Asn Tyr 115 120 125Asp Cys Asn Tyr Gln Pro Tyr Gly Asn Ser Tyr Leu Cys Val Tyr Gly 130 135 140Trp Thr Ser Ser Pro Leu Val Glu Tyr Tyr Ile Val Asp Ser Trp Gly145 150 155 160Ser Trp Arg Pro Pro Gly Gly Thr Ser Lys Gly Thr Ile Thr Val Asp 165 170 175Gly Gly Ile Tyr Asp Ile Tyr Glu Thr Thr Arg Ile Asn Gln Pro Ser 180 185 190Ile Gln Gly Asn Thr Thr Phe Lys Gln Tyr Trp Ser Val Arg Arg Thr 195 200 205Lys Arg Thr Ser Gly Thr Ile Ser Val Ser Lys His Phe Ala Ala Trp 210 215 220Glu Ser Lys Gly Met Pro Leu Gly Lys Met His Glu Thr Ala Phe Asn225 230 235 240Ile Glu Gly Tyr Gln Ser Ser Gly Lys Ala Asp Val Asn Ser Met Ser 245 250 255Ile Asn Ile Gly Lys 26058234PRTC. thermocellum 58Met Lys Gln Lys Leu Leu Val Thr Phe Leu Ile Leu Ile Thr Phe Thr1 5 10 15Val Ser Leu Thr Leu Phe Pro Val Asn Val Arg Ala Asp Val Val Ile 20 25 30Thr Ser Asn Gln Thr Gly Thr Gly Gly Gly Tyr Asn Phe Glu Tyr Trp 35 40 45Lys Asp Thr Gly Asn Gly Thr Met Val Leu Lys Asp Gly Gly Ala Phe 50 55 60Ser Cys Glu Trp Ser Asn Ile Asn Asn Ile Leu Phe Arg Lys Gly Phe65 70 75 80Lys Tyr Asp Glu Thr Lys Thr His Asp Gln Leu Gly Tyr Ile Thr Val 85 90 95Thr Tyr Ser Cys Asn Tyr Gln Pro Asn Gly Asn Ser Tyr Leu Gly Val 100 105 110Tyr Gly Trp Thr Ser Asn Pro Leu Val Glu Tyr Tyr Ile Ile Glu Ser 115 120 125Trp Gly Thr Trp Arg Pro Pro Gly Ala Thr Pro Lys Gly Thr Ile Thr 130 135 140Val Asp Gly Gly Thr Tyr Glu Ile Tyr Glu Thr Thr Arg Val Asn Gln145 150 155 160Pro Ser Ile Lys Gly Thr Ala Thr Phe Gln Gln Tyr Trp Ser Val Arg 165 170 175Thr Ser Lys Arg Thr Ser Gly Thr Ile Ser Val Thr Glu His Phe Lys 180 185 190Ala Trp Glu Arg Leu Gly Met Lys Met Gly Lys Met Tyr Glu Val Ala 195 200 205Leu Val Val Glu Gly Tyr Gln Ser Ser Gly Lys Ala Asp Val Thr Ser 210 215 220Met Thr Ile Thr Val Gly Asn Ala Pro Ser225 23059230PRTBacillus sp 41M-1 59Met Lys Gln Val Lys Ile Met Phe Leu Met Thr Met Phe Leu Gly Ile1 5 10 15Gly Leu Leu Phe Phe Ser Glu Asn Ala Glu Ala Ala Ile Thr Ser Asn 20 25 30Glu Ile Gly Thr His Asp Gly Tyr Asp Tyr Glu Phe Trp Lys Asp Ser 35 40 45Gly Gly Ser Gly Ser Met Thr Leu Asn Ser Gly Gly Thr Phe Ser Ala 50 55 60Gln Trp Ser Asn Val Asn Asn Ile Leu Phe Arg Lys Gly Lys Lys Phe65 70 75 80Asp Glu Thr Gln Thr His Gln Gln Ile Gly Asn Met Ser Ile Asn Tyr 85 90 95Gly Ala Thr Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Thr Val Tyr Gly 100 105 110Trp Thr Val Asp Pro Leu Val Glu Phe Tyr Ile Val Asp Ser Trp Gly 115 120 125Thr Trp Arg Pro Pro Gly Gly Thr Pro Lys Gly Thr Ile Asn Val Asp 130 135 140Gly Gly Thr Tyr Gln Ile Tyr Glu Thr Thr Arg Tyr Asn Gln Pro Ser145 150 155 160Ile Lys Gly Thr Ala Thr Phe Gln Gln Tyr Trp Ser Val Arg Thr Ser 165 170 175Lys Arg Thr Ser Gly Thr Ile Ser Val Ser Glu His Phe Arg Ala Trp 180 185 190Glu Ser Leu Gly Met Asn Met Gly Asn Met Tyr Glu Val Ala Leu Thr 195 200 205Val Glu Gly Tyr Gln Ser Ser Gly Ser Ala Asn Val Tyr Ser Asn Thr 210 215 220Leu Thr Ile Gly Gly Gln225 23060217PRTP. multivesiculatum 60Glu Lys Val Ile Cys Leu Leu Ile Ala Leu Phe Gly Leu Ile Glu Ala1 5 10 15Gln Thr Phe Tyr Asn Asn Ala Gln Gly Gln Ile Asp Gly Leu Asp Tyr 20 25 30Glu Leu Trp Lys Asp Thr Gly Thr Thr Ser Met Thr Leu Leu Gly Gly 35 40 45Gly Lys Phe Ser Cys Ser Trp Ser Asn Ile Asn Asn Cys Leu Phe Arg 50 55 60Ile Gly Lys Lys Trp Asn Cys Gln Tyr Glu Trp Trp Glu Leu Gly Thr65 70 75 80Val Leu Val Asn Tyr Asp Val Asp Tyr Asn Pro Asn Gly Asn Ser Tyr 85 90 95Leu Cys Ile Tyr Gly Trp Thr Arg Asn Pro Leu Val Glu Tyr Tyr Ile 100 105 110Val Glu Ser Trp Gly Ser Trp Arg Pro Pro Gly Gly Ser Pro Met Asn 115 120 125Thr Met Tyr Val Asp Asp Gly Gln Tyr Asp Val Tyr Val Thr Asp Arg 130 135 140Ile Asn Gln Pro Ser Ile Asp Gly Asn Thr Asn Phe Lys Gln Tyr Trp145 150 155 160Ser Val Arg Thr Gln Lys Lys Thr Arg Gly Thr Val His Val Asn His 165 170 175His Phe Tyr Asn Trp Gln Glu Met Gly Leu Lys Val Gly Lys Val Tyr 180 185 190Glu Ala Ser Leu Asn Ile Glu Gly Tyr Gln Ser Ala Gly Ser Ala Thr 195 200 205Val Asn Lys Asn Glu Val Val Gln Thr 210 21561175PRTP multivesiculatum 61Met Thr Leu Leu Gly Gly Gly Lys Phe Ser Cys Asn Trp Ser Asn Ile1 5 10 15Gly Asn Ala Leu Phe Arg Ile Gly Lys Lys Trp Asp Cys Thr Lys Thr 20 25 30Trp Gln Gln Leu Gly Thr Ile Ser Val Ala Tyr Asn Val Asp Tyr Arg 35 40 45Pro Asn Gly Asn Ser Tyr Met Cys Val Tyr Gly Trp Thr Arg Ser Pro 50 55 60Leu Ile Glu Tyr Tyr Ile Val Asp Ser Trp Gly Ser Trp Arg Pro Pro65 70 75 80Gly Ser Asn Ser Met Gly Thr Ile Asn Val Asp Gly Gly Thr Tyr Asp 85 90 95Ile Tyr Val Thr Asp Arg Ile Asn Gln Pro Ser Ile Asp Gly Thr Thr 100 105 110Thr Phe Lys Gln Phe Trp Ser Val Arg Thr Gln Lys Lys Thr Ser Gly 115 120 125Val Ile Ser Val Ser Lys His Phe Glu Ala Trp Thr Ser Lys Gly Leu 130 135 140Asn Leu Gly Leu Met Tyr Glu Ala Ser Leu Thr Ile Glu Gly Tyr Gln145 150 155 160Ser Ser Gly Ser Ala Thr Val Asn Gln Asn Asp Val Thr Gly Gly 165 170 17562265PRTR. albus 62Met Arg Asn Asn Phe Lys Met Arg Val Met Ala Gly Val Ala Ala Val1 5 10 15Ile Cys Leu Ala Gly Val Leu Gly Ser Cys Gly Asn Ser Ser Asp Lys 20 25 30Asp Ser Ser Ser Lys Lys Ser Ala Asp Ser Ala Lys Ala Asp Ser Asn 35 40 45Lys Asp Ser Lys Asn Gly Gln Val Phe Thr Lys Asn Ala Arg Gly Thr 50 55 60Ser Asp Gly Tyr Asp Tyr Glu Leu Trp Lys Asp Lys Gly Asp Thr Glu65 70 75 80Met Thr Ile Asn Glu Gly Gly Thr Phe Ser Cys Lys Trp Ser Asn Ile 85 90 95Asn Asn Ala Leu Phe Arg Arg Gly Lys Lys Phe Asp Cys Thr Lys Thr 100 105 110Tyr Lys Glu Leu Gly Asn Ile Ser Val Lys Tyr Gly Val Asp Tyr Gln 115 120 125Pro Asp Gly Asn Ser Tyr Met Cys Val Tyr Gly Trp Thr Ile Asp Pro 130 135 140Leu Val Glu Phe Tyr Ile Val Glu Ser Trp Gly Ser Trp Arg Pro Pro145 150 155 160Gly Ala Ala Glu Ser Leu Gly Thr Val Thr Val Asp Gly Gly Thr Tyr 165 170 175Asp Ile Tyr Lys Thr Thr Arg Tyr Glu Gln Pro Ser Ile Asp Gly Thr 180 185 190Lys Thr Phe Asp Gln Tyr Trp Ser Val Arg Gln Asp Lys Pro Thr Gly 195 200 205Asp Gly Thr Lys Ile Glu Gly Thr Ile Ser Ile Ser Lys His Phe Asp 210 215 220Ala Trp Glu Gln Val Gly Leu Thr Leu Gly Asn Met Tyr Glu Val Ala225 230 235 240Leu Asn Ile Glu Gly Tyr Gln Ser Asn Gly Gln Ala Thr Ile Tyr Glu 245 250 255Asn Glu Leu Thr Val Asp Gly Asn Tyr 260 26563226PRTCaldicellulosiruptor sp 63Met Cys Val Val Leu Ala Asn Pro Phe Tyr Ala Gln Ala Ala Met Thr1 5 10 15Phe Thr Ser Asn Ala Thr Gly Thr Tyr Asp Gly Tyr Tyr Tyr Glu Leu 20 25 30Trp Lys Asp Thr Gly Asn Thr Thr Met Thr Val Asp Thr Gly Gly Arg 35 40 45Phe Ser Cys Gln Trp Ser Asn Ile Asn Asn Ala Leu Phe Arg Thr Gly 50 55 60Lys Lys Phe Ser Thr Ala Trp Asn Gln Leu Gly Thr Val Lys Ile Thr65 70 75 80Tyr Ser Ala Thr Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Cys Ile Tyr 85 90 95Gly Trp Ser Arg Asn Pro Leu Val Glu Phe Tyr Ile Val Glu Ser Trp 100 105 110Gly Ser Trp Arg Pro Pro Gly Ala Thr Ser Leu Gly Thr Val Thr Ile 115 120 125Asp Gly Ala Thr Tyr Asp Ile Tyr Lys Thr Thr Arg Val Asn Gln Pro 130 135 140Ser Ile Glu Gly Thr Arg Thr Phe Asp Gln Tyr Trp Ser Val Arg Thr145 150 155 160Ser Lys Arg Thr Ser Gly Thr Val Thr Val Thr Asp His Phe Lys Ala 165 170 175Trp Ala Ala Lys Gly Leu Asn Leu Gly Thr Ile Asp Gln Ile Thr Leu 180 185 190Cys Val Glu Gly Tyr Gln Ser Ser Gly Ser Ala Asn Ile Thr Gln Asn 195 200 205Thr Phe Thr Ile Gly Gly Ser Ser Ser Gly Ser Ser Asn Gly Ser Asn 210 215 220Asn Gly22564232PRTD. thermophilum 64Met Phe Leu Lys Lys Leu Ser Lys Leu Leu Leu Val Val Leu Leu Val1 5 10 15Ala Val Tyr Thr Gln Val Asn Ala Gln Thr Ser Ile Thr Leu Thr Ser 20 25 30Asn Ala Ser Gly Thr Phe Asp Gly Tyr Tyr Tyr Glu Leu Trp Lys Asp 35 40 45Thr Gly Asn Thr Thr Met Thr Val Tyr Thr Gln Gly Arg Phe Ser Cys 50 55 60Gln Trp Ser Asn Ile Asn Asn Ala Leu Phe Arg Thr Gly Lys Lys Tyr65 70 75 80Asn Gln Asn Trp Gln Ser Leu Gly Thr Ile Arg Ile Thr Tyr Ser Ala 85 90 95Thr Tyr Asn Pro Asn Gly Asn Ser Tyr Leu Cys Ile Tyr Gly Trp Ser 100 105 110Thr Asn Pro Leu Val Glu Phe Tyr Ile Val Glu Ser Trp Gly Asn Trp 115 120 125Arg Pro Pro Gly Ala Thr Ser Leu Gly Gln Val Thr Ile Asp Gly Gly 130 135 140Thr Tyr Asp Ile Tyr Arg Thr Thr Arg Val Asn Gln Pro Ser Ile Val145 150 155 160Gly Thr Ala Thr Phe Asp Gln Tyr Trp Ser Val Arg Thr Ser Lys Arg 165 170 175Thr Ser Gly Thr Val Thr Val Thr Asp His Phe Arg Ala Trp Ala Asn 180 185 190Arg Gly Leu Asn Leu Gly Thr Ile Asp Gln Ile Thr Leu Cys Val Glu 195 200 205Gly Tyr Gln Ser Ser Gly Ser Ala Asn Ile Thr Gln Asn Thr Phe Ser 210 215 220Gln Gly Ser Ser Ser Gly Ser Ser225 23065255PRTR. flavefaciens 65Met Lys Leu Ser Lys Ile Lys Lys Val Leu Ser Gly Thr Val Ser Ala1 5 10 15Leu Met Ile Ala Ser Ala Ala Pro Val Val Ala Ser Ala Ala Asp Gln 20 25 30Gln Thr Arg Gly Asn Val Gly Gly Tyr Asp Tyr Glu Met Trp Asn Gln 35 40 45Asn Gly Gln Gly Gln Ala Ser Met Asn Pro Gly Ala Gly Ser Phe Thr 50 55 60Cys Ser Trp Ser Asn Ile Glu Asn Phe Leu Ala Arg Met Gly Lys Asn65 70 75 80Tyr Asp Ser Gln Lys Lys Asn Tyr Lys Ala Phe Gly Asn Ile Val Leu 85 90 95Thr Tyr Asp Val Glu Tyr Thr Pro Arg Gly Asn Ser Tyr Met Cys Val 100 105 110Tyr Gly Trp Thr Arg Asn Pro Leu Met Glu Tyr Tyr Ile Val Glu Gly 115 120 125Trp Gly Asp Trp Arg Pro Pro Gly Asn Asp Gly Glu Val Lys Gly Thr 130 135 140Val Ser Ala Asn Gly Asn Thr Tyr Asp Ile Arg Lys Thr Met Arg Tyr145 150 155 160Asn Gln Pro Ser Leu Asp Gly Thr Ala Thr Phe Pro Gln Tyr Trp Ser 165 170 175Val Arg Gln Thr Ser Gly Ser Ala Asn Asn Gln Thr Asn Tyr Met Lys 180 185 190Gly Thr Ile Asp Val Thr Lys His Phe Asp Ala Trp Ser Ala Ala Gly 195 200 205Leu Asp Met Ser Gly Thr Leu Tyr Glu Val Ser Leu Asn Ile Glu Gly 210 215 220Tyr Arg Ser Asn Gly Ser Ala Asn Val Lys Ser Val Ser Val Thr Gln225 230 235 240Gly Gly Ser Ser Asp Asn Gly Gly Gln Gln Gln Asn Asn Asp Trp 245 250 25566280PRTP. stipitis 66Met Thr Val Tyr Lys Arg Lys Ser Arg Val Leu Ile Ala Val Val Thr1 5 10 15Leu Leu His Val Leu Ser His Ala Pro Thr Lys Met Leu Thr Thr Asp 20 25 30Val Leu Leu Thr Arg Cys Met His Leu Cys His Phe Arg Thr Ser Asp 35 40 45Ser Val Tyr Thr Asn Glu Thr Ser Glu Glu Arg Ser Met Ser Asp Arg 50 55 60Leu Asn Ile Thr Arg Val Met Ser Tyr Asp Arg Trp Thr Asp Leu Val65 70 75 80Gly Glu Leu Glu Val Arg Glu Leu Lys His Val Met Ser His Arg Thr 85 90 95Tyr Ser Leu Cys Asp Leu Ser Cys Ser Thr Val Leu Asp Ser Asn Ser 100 105 110Met Phe Ser Leu Gly Lys Gly Trp Gln Ala Ile Ser Ser Arg Gln Gly 115 120 125Val Gly Ala Thr Val Tyr Gly Trp Thr Arg Ser Pro Leu Leu Ile Glu 130 135 140Tyr Tyr Val Val Asp Ser Trp Gly Ser Tyr His Pro Ser Asn Thr Ile145 150 155 160Thr Gly Thr Phe Val Thr Val Lys Cys Asp Gly Gly Thr Tyr Asp Ile 165 170 175Tyr Thr Ala Val Arg Val Asn Ala Pro Ser Ile Glu Gly Thr Thr Phe 180 185 190Thr Gln Tyr Trp Ser Val Arg Gln Ser Ala Thr Ile Gln Leu Ala Val 195 200 205Ile Lys Pro Leu Thr Leu Gln Asn Ala Thr Ile Thr Phe Thr Phe Ser 210 215 220Asn His Phe Asp Ala Trp Lys Thr Met Thr Leu Glu Ala Thr His Ser225 230 235 240Thr Glu Gly Tyr Phe Ser Ser Gly Ile Thr Tyr Glu Gln Pro His Gln 245 250 255Pro His Arg Asn Thr Trp Ala Thr Ser Leu Thr Ser Gln Thr Lys His 260 265

270Thr Ala Arg Ser Leu Pro Ile Asn 275 280

Claims

1-22. (canceled)

23. A method of degrading or modifying a plant cell wall which method comprises contacting said plant cell wall with a polypeptide, wherein said polypeptide is a variant xylanase polypeptide, or fragment thereof having xylanase activity; wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, comprises one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme.

24. A method according to claim 23 wherein said polypeptide is derived from a family 11 xylanase.

25. A method according to claim 23 wherein said amino acid modification is of one or more surface amino acid residues.

26. A method according to claim 23 wherein said amino acid modification is of one or more solvent accessible residues.

27. A method according to claim 23 wherein there are at least two of said amino acid modifications.

28. A method according to claim 23 wherein said amino acid modification is at any one or more of amino acid residues: Ala1-Trp6, Asn8, Thr10-Gly23, Asn25, Ser27, Asn29, Ser31-Asn32, Gly34, Thr43-Thr44, Ser46-Thr50, Asn52, Asn54, Gly56-Asn61, Asn63, Arg73-Leu76, Thr87-Arg89, Thr91-Lys95, Thr97, Lys99, Asp101-Gly102, Thr104, Thr109-Thr111, Tyr113-Asn114, Asp119-Thr124, Thr126, Gln133-Asn141, Thr143, Thr145, Thr147-Asn148, Asn151, Lys154-Gly157, Asn159-Leu160, Ser162-Trp164, Gln175, Ser177, Ser179, Asn181, Thr183, of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or its/their equivalent positions in other homologous xylanase polypeptides.

29. A method according to claim 23 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

30. A method according to claim 23 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues.

31. A method according to claim 23 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues; and wherein said other amino acid residues are any one or more of amino acid residues numbers: 3, 4, 5, 6, 7, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 108, 109, 110, 126, 127, 128, 129, 130, 131, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 179, 180, 181, 182, 183 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

32. A method according to claim 23 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues; and wherein said other surface amino acid residues are any one or more of amino acid residues numbers: 1, 2, 46, 47, 48, 49, 50, 51, 52, 53, 54, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 184, 185 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

33. A method according to claim 23 wherein the inhibitor is an inhibitor found naturally in plant tissues.

34. A method according to claim 23 wherein the sensitivity to the inhibitor is reduced.

35. A method of processing a plant material which method comprises contacting said plant material with a polypeptide, wherein said polypeptide is a variant xylanase polypeptide, or fragment thereof having xylanase activity; wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, comprises one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme.

36. A method according to claim 35 wherein said polypeptide is derived from a family 11 xylanase.

37. A method according to claim 35 wherein said amino acid modification is of one or more surface amino acid residues.

38. A method according to claim 35 wherein said amino acid modification is of one or more solvent accessible residues.

39. A method according to claim 35 wherein there are at least two of said amino acid modifications.

40. A method according to claim 35 wherein said amino acid modification is at any one or more of amino acid residues: Ala1-Trp6, Asn8, Thr10-Gly23, Asn25, Ser27, Asn29, Ser31-Asn32, Gly34, Thr43-Thr44, Ser46-Thr50, Asn52, Asn54, Gly56-Asn61, Asn63, Arg73-Leu76, Thr87-Arg89, Thr91-Lys95, Thr97, Lys99, Asp101-Gly102, Thr104, Thr109-Thr111, Tyr113-Asn114, Asp119-Thr124, Thr126, Gln133-Asn141, Thr143, Thr145, Thr147-Asn148, Asn151, Lys154-Gly157, Asn159-Leu160, Ser162-Trp164, Gln175, Ser177, Ser179, Asn181, Thr183, of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or its/their equivalent positions in other homologous xylanase polypeptides.

41. A method according to claim 35 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

42. A method according to claim 35 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues.

43. A method according to claim 35 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues; and wherein said other amino acid residues are any one or more of amino acid residues numbers: 3, 4, 5, 6, 7, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 108, 109, 110, 126, 127, 128, 129, 130, 131, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 179, 180, 181, 182, 183 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

44. A method according to claim 35 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues; and wherein said other surface amino acid residues are any one or more of amino acid residues numbers: 1, 2, 46, 47, 48, 49, 50, 51, 52, 53, 54, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 184, 185 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

45. A method according to claim 35 wherein the inhibitor is an inhibitor found naturally in plant tissues.

46. A method according to claim 35 wherein the sensitivity to the inhibitor is reduced.

47. A method of baking or processing cereals or starch production or processing wood or enhancing the bleaching of wood pulp which method comprises the use of a polypeptide, wherein said polypeptide is a variant xylanase polypeptide, or fragment thereof having xylanase activity; wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, comprises one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme.

48. A method according to claim 47 wherein said polypeptide is derived from a family 11 xylanase.

49. A method according to claim 47 wherein said amino acid modification is of one or more surface amino acid residues.

50. A method according to claim 47 wherein said amino acid modification is of one or more solvent accessible residues.

51. A method according to claim 47 wherein there are at least two of said amino acid modifications.

52. A method according to claim 47 wherein said amino acid modification is at any one or more of amino acid residues: Ala1-Trp6, Asn8, Thr10-Gly23, Asn25, Ser27, Asn29, Ser31-Asn32, Gly34, Thr43-Thr44, Ser46-Thr50, Asn52, Asn54, Gly56-Asn61, Asn63, Arg73-Leu76, Thr87-Arg89, Thr91-Lys95, Thr97, Lys99, Asp101-Gly102, Thr104, Thr109-Thr111, Tyr113-Asn114, Asp119-Thr124, Thr126, Gln133-Asn141, Thr143, Thr145, Thr147-Asn148, Asn151, Lys154-Gly157, Asn159-Leu160, Ser162-Trp164, Gln175, Ser177, Ser179, Asn181, Thr183, of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or its/their equivalent positions in other homologous xylanase polypeptides.

53. A method according to claim 47 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

54. A method according to claim 47 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues.

55. A method according to claim 47 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues; and wherein said other amino acid residues are any one or more of amino acid residues numbers: 3, 4, 5, 6, 7, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 108, 109, 110, 126, 127, 128, 129, 130, 131, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 179, 180, 181, 182, 183 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

56. A method according to claim 47 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues; and wherein said other surface amino acid residues are any one or more of amino acid residues numbers: 1, 2, 46, 47, 48, 49, 50, 51, 52, 53, 54, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 184, 185 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

57. A method according to claim 47 wherein the inhibitor is an inhibitor found naturally in plant tissues.

58. A method according to claim 47 wherein the sensitivity to the inhibitor is reduced.

59. A nucleotide sequence encoding a variant polypeptide, wherein said polypeptide is a variant xylanase polypeptide, or fragment thereof having xylanase activity; wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, comprises one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme.

60. A nucleotide sequence according to claim 59 wherein said polypeptide is derived from a family 11 xylanase.

61. A nucleotide sequence according to claim 59 wherein said amino acid modification is of one or more surface amino acid residues.

62. A nucleotide sequence according to claim 59 wherein said amino acid modification is of one or more solvent accessible residues.

63. A nucleotide sequence according to claim 59 wherein there are at least two of said amino acid modifications.

64. A nucleotide sequence according to claim 59 wherein said amino acid modification is at any one or more of amino acid residues: Ala1-Trp6, Asn8, Thr10-Gly23, Asn25, Ser27, Asn29, Ser31-Asn32, Gly34, Thr43-Thr44, Ser46-Thr50, Asn52, Asn54, Gly56-Asn61, Asn63, Arg73-Leu76, Thr87-Arg89, Thr91-Lys95, Thr97, Lys99, Asp101-Gly102, Thr104, Thr109-Thr111, Tyr113-Asn114, Asp119-Thr124, Thr126, Gln133-Asn141, Thr143, Thr145, Thr147-Asn148, Asn151, Lys154-Gly157, Asn159-Leu160, Ser162-Trp164, Gln175, Ser177, Ser179, Asn181, Thr183, of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or its/their equivalent positions in other homologous xylanase polypeptides.

65. A nucleotide sequence according to claim 59 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

66. A nucleotide sequence according to claim 59 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues.

67. A nucleotide sequence according to claim 59 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues; and wherein said other amino acid residues are any one or more of amino acid residues numbers: 3, 4, 5, 6, 7, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 108, 109, 110, 126, 127, 128, 129, 130, 131, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 179, 180, 181, 182, 183 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

68. A nucleotide sequence according to claim 59 wherein said amino acid modification is at any one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides; and wherein said variant xylanase polypeptide, or fragment thereof having xylanase activity, in addition comprises one or more amino acid modifications at any one of the other amino acid residues; and wherein said other surface amino acid residues are any one or more of amino acid residues numbers: 1, 2, 46, 47, 48, 49, 50, 51, 52, 53, 54, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 184, 185 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.

69. A nucleotide sequence according to claim 59 wherein the inhibitor is an inhibitor found naturally in plant tissues.

70. A nucleotide sequence according to claim 59 wherein the sensitivity to the inhibitor is reduced.

71. A method according to claim 23 wherein said polypeptide has at least 40% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

72. A method according to claim 23 wherein said polypeptide has at least 50% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

73. A method according to claim 23 wherein said polypeptide has at least 60% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

74. A method according to claim 23 wherein said polypeptide has at least 80% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

75. A method according to claim 35 wherein said polypeptide has at least 40% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

76. A method according to claim 35 wherein said polypeptide has at least 50% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

77. A method according to claim 35 wherein said polypeptide has at least 60% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

78. A method according to claim 35 wherein said polypeptide has at least 80% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

79. A method according to claim 47 wherein said polypeptide has at least 40% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

80. A method according to claim 47 wherein said polypeptide has at least 50% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

81. A method according to claim 47 wherein said polypeptide has at least 60% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

82. A method according to claim 47 wherein said polypeptide has at least 80% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

83. A nucleotide sequence according to claim 59 wherein said polypeptide has at least 40% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

84. A nucleotide sequence according to claim 59 wherein said polypeptide has at least 50% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

85. A nucleotide sequence according to claim 59 wherein said polypeptide has at least 60% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

86. A nucleotide sequence according to claim 59 wherein said polypeptide has at least 80% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package.

87. A method according to claim 23 wherein said polypeptide is derivable from SEQ ID NO: 9.

88. A method according to claim 35 wherein said polypeptide is derivable from SEQ ID NO: 9.

89. A method according to claim 47 wherein said polypeptide is derivable from SEQ ID NO: 9.

90. A nucleotide sequence according to claim 59 wherein said polypeptide is derivable from SEQ ID NO: 9.

91. An isolated variant polypeptide or fragment thereof having at least 40% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package, and having xylanase activity, comprising two or more amino acid modifications, wherein said amino acid modifications are at two or more of positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ ID NO: 1, or their equivalent positions in other family 11 xylanases, such that the polypeptide or fragment thereof has altered sensitivity to a xylanase inhibitor as compared with the parent xylanase, wherein one of said modifications is at position 11, wherein the variant polypeptide is a family 11 xylanase.

92. An isolated variant polypeptide or fragment thereof having at least 50% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package, and having xylanase activity, comprising two or more amino acid modifications, wherein said amino acid modifications are at two or more of positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ ID NO: 1, or their equivalent positions in other family 11 xylanases, such that the polypeptide or fragment thereof has altered sensitivity to a xylanase inhibitor as compared with the parent xylanase, wherein one of said modifications is at position 11, wherein the variant polypeptide is a family 11 xylanase.

93. An isolated variant polypeptide or fragment thereof having at least 60% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package, and having xylanase activity, comprising two or more amino acid modifications, wherein said amino acid modifications are at two or more of positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ ID NO: 1, or their equivalent positions in other family 11 xylanases, such that the polypeptide or fragment thereof has altered sensitivity to a xylanase inhibitor as compared with the parent xylanase, wherein one of said modifications is at position 11, wherein the variant polypeptide is a family 11 xylanase.

94. A variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from SEQ ID No. 9.

95. A variant xylanase polypeptide, or fragment thereof having at least 40% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package and having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from SEQ ID No. 9.

96. A variant xylanase polypeptide, or fragment thereof having at least 50% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package and having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from SEQ ID No. 9.

97. A variant xylanase polypeptide, or fragment thereof having at least 60% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package and having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from SEQ ID No. 9.

98. A variant xylanase polypeptide, or fragment thereof having at least 80% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package and having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from SEQ ID No. 9.

99. A method according to claim 23 wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00019 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

100. A method according to claim 35 wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00020 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

101. A method according to claim 47 wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00021 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

102. A nucleotide sequence according to claim 59 wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00022 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

103. A variant xylanase polypeptide, or fragment thereof having at least 40% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package and having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00023 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

104. A variant xylanase polypeptide, or fragment thereof having at least 50% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package and having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00024 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

105. A variant xylanase polypeptide, or fragment thereof having at least 60% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package and having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00025 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

106. A variant xylanase polypeptide, or fragment thereof having at least 80% homology to SEQ ID NO: 1 as determined by using the GCG Wisconsin Bestfit package and having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00026 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn

107. A variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme; wherein the variant polypeptide is derived from a family 11 xylanase; wherein said amino acid modification is of two or more surface amino acid residues; wherein said amino acid modification is at an equivalent position to one or more of amino acid residues numbers: 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; wherein one of said modifications is at an equivalent position to amino acid residue number 11 of the B. subtilis amino acid sequence shown as SEQ I.D. No. 1; and wherein said polypeptide is derivable from any of the xylanase sequences presented in FIG. 2 or referred to in the following Table: TABLE-US-00027 Aspergillus niger Xyn A Aspergillus kawachii Xyn C Aspergillus tubigensis Xyn A Bacillus circulans Xyn A Bacillus pumilus Xyn A Bacillus subtilis Xyn A Cellulomonas fimi Xyn D Chainia spp. Xyn Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A Nocardiopsis dassonvillei Xyn II Ruminococcus flavefaciens Xyn A Schizophyllum commune Xyn Streptomyces lividans Xyn B Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A Trichoderma harzianum Xyn Trichoderma reesei Xyn I Trichoderma reesei Xyn II Trichoderma viride Xyn